Document:

EX-10.6

 Exhibit 10.6 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(c) and Rule 406 of the 

Securities Act of 1933, as amended. 
  

 
  
  

 
  
  

RESEARCH FUNDING AND OPTION AGREEMENT 
 by and
between 
 THE SCRIPPS RESEARCH INSTITUTE 
 a
California nonprofit 
 public benefit corporation 

and         

Synthorx, Inc., 
 a Delaware corporation 

 

 RESEARCH FUNDING AND OPTION AGREEMENT 

This Agreement is entered into this 31st day of July, 2014 (the “Effective
Date”), by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 (“TSRI”), and Synthorx, Inc., a Delaware corporation,
located at 11099 North Torrey Pines Road, La Jolla, California 92037 (“Sponsor”), with respect to the facts set forth below. 

RECITALS 

A.        TSRI is engaged in fundamental scientific biomedical and biochemical research
including research relating to synthetic DNA bases, as more particularly described herein. 

B.        Sponsor is engaged in the research and development of novel proteins, RNA and DNA for
medical applications. 
 C.        Sponsor desires to provide certain funding as part of
TSRI’s research activities described above. 
 D.        Subject to any non-exclusive rights of the U.S. Government, TSRI is willing to grant to Sponsor an option to acquire rights and licenses to certain intellectual property arising from the Research Program (as defined below). 

E.        TSRI and Sponsor are parties to a license agreement dated as of the Effective Date
(the “Exclusive License Agreement”), pursuant to which TSRI has granted Sponsor an exclusive license under certain technology, materials and other information existing on the Effective Date, including TSRI’s patent and other
intellectual property rights therein (collectively, the “Existing Technology”). 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual covenants and conditions outlined herein, TSRI and Sponsor hereby agree as follows: 

1.        DEFINITIONS. 

1.1      Affiliate. The term “Affiliate” shall mean any entity which directly or
indirectly controls, or is controlled by Sponsor. The term “control” as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for
the election of directors; or (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and
policies of such non-corporate entities. Unless otherwise specified, the term Sponsor includes Affiliates. 

  
 -1- 

 1.2      Agreement Number.  This
Agreement is TSRI number SFP-2143. 
 1.3      Biological
Materials.  The term “Biological Materials” shall mean any Technology in the form of tangible materials together with any progeny, mutants, or derivatives thereof developed in performance of the Research Program. 

1.4      Confidential Information.    The term “Confidential
Information” shall mean any and all proprietary information of TSRI or Sponsor which may be disclosed or made available by such party (the “disclosing party”) to the other party (the “receiving party”) at any time and from
time to time during the term hereof. The fact that a disclosing party may have marked or identified as confidential or proprietary any specific information shall be indicative that such disclosing party believes such information to be confidential
or proprietary, but the failure to so mark information shall not conclusively determine that such information was or was not considered confidential information by such disclosing party. Confidential Information shall also include any information
which, given the circumstances surrounding the disclosure, would be considered confidential by the disclosing party. Information shall not be considered confidential to the extent that the receiving party can demonstrate by competent proof that such
information: 
   a.        Is in the public domain at the time of disclosure to the
receiving party; or 
   b.        After disclosure to the receiving party, becomes
part of the public domain, by publication or otherwise, without any breach of this Agreement by the receiving party; or 

  c.        Was known to the receiving party prior to the Effective Date, which
knowledge was acquired independently and not from the disclosing party (including the disclosing party’s employees); or 

  d.        Is subsequently disclosed to the receiving party in good faith by a third
party who has a right to make such disclosure. 
 1.5      Field. The term
“Field” shall mean [...***...]. 
 1.6      Joint Technology.  The term
“Joint Technology” shall mean any Technology made or developed jointly by at least one employee or consultant of Sponsor (it being understood that, for purposes of this paragraph, no TSRI employee shall be considered a consultant of
Sponsor) and at least one employee of TSRI, as determined under principles of inventorship under US patent law. 

1.7      Patent Rights.  The term “Patent Rights” shall mean rights arising out
of or resulting from (a) U.S./PCT patent application(s) directed to the Technology; (b) divisionals, continuations, reissues, reexaminations, and extensions of any patent or application set forth in sub clause (a) above;
(c) foreign counterparts of any of the foregoing; 

  
 ***Confidential
Treatment Requested 
 -2- 

 (d) patents issued from the application(s) referenced in sub clauses (a) – (c) above; and (e) all
claims of continuations-in-part that are entitled to the benefit of the priority date of the application(s) referenced in sub clause (a) above. 

1.8      Principal Investigator.    The term “Principal Investigator”
shall mean Dr. Floyd E. Romesberg, together with such replacement persons selected in accordance with the provisions of Section 2.2 below. 

1.9      Research Program.  The term “Research Program” shall mean the research
program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto. 

1.10    Research Tool.    The term “Research Tool” shall mean any Technology
which is designed or utilized for basic research purposes or internal drug discovery purposes and which is not utilized to produce, or incorporated into, a product. 

1.11    Technology.    The term “Technology” shall mean any invention,
discovery, know-how, biological material, software, information and data, whether patentable or not, conceived and reduced to practice during the performance of the Research Program. 

1.12    TSRI Technology.    The term “TSRI Technology” shall mean any
Technology, made or developed solely by one or more employees of TSRI, as determined under principles of inventorship under U.S. patent law. 

2.        CONDUCT OF RESEARCH PROGRAM. 

2.1      Conduct of Research Program.  TSRI hereby agrees to use [...***...] to
perform the Research Program subject to the provisions of this Agreement. Notwithstanding the foregoing, TSRI makes no warranties or representations regarding its ability to achieve, nor shall it be bound to accomplish, any particular research
objective or results. 
 2.2      Supervision of Research Program.  TSRI agrees that
the Research Program at TSRI shall be conducted by or under the direct supervision of the Principal Investigator. In the event that the Principal Investigator leaves TSRI, or terminates his/her involvement in the Research Program, TSRI shall use its
best efforts to find a replacement Principal Investigator acceptable to Sponsor, which acceptance shall not be unreasonably withheld. In the event that TSRI shall fail to appoint a replacement Principal Investigator reasonably acceptable to Sponsor,
Sponsor shall have a right to terminate this Agreement upon delivery to TSRI of written notice of termination pursuant to this Section 2.2, which notice must be delivered to TSRI not more than ninety (90) days after delivery by TSRI to
Sponsor of the name of the proposed replacement Principal Investigator. 

2.3      Reports.  TSRI and the Principal Investigator shall keep complete and accurate
records of the results of the Research Program. TSRI agrees to provide oral 

  
 ***Confidential
Treatment Requested 
 -3- 

 
reports on a monthly basis, and Sponsor shall have the right, upon reasonable request from time to time, to discuss with TSRI, the Principal Investigator and other appropriate TSRI personnel, in
person or otherwise, the Research Program and the results thereof. TSRI agrees that within [...***...] following the last day of each calendar year during the term of this Agreement, TSRI shall furnish Sponsor with a written report summarizing
the results of the research included within the scope of the Research Program conducted by TSRI, during the immediately preceding calendar year, including but not limited to all data, conclusions, results, observations and a detailed description of
all procedures. Subject to Section 5.1, all such reports shall be treated as Confidential Information by Sponsor. In the event that Sponsor identifies any Technology disclosed in such report as to which it would like to exercise its option and
which has not been previously disclosed to Sponsor by TSRI in accordance with Section 3.2, Sponsor shall notify TSRI of such Technology in writing. Promptly following such notification, TSRI shall provide Sponsor with a Technology Disclosure in
accordance with Section 3.2. 
 2.4      Financial and Staffing Obligations 

  a.        Contributions of Parties to Research Program. Contributions in the
form of financial support, equipment, personnel, technology and other necessary components for the conduct of the Research Program shall be made by the parties in accordance with the terms set forth on Exhibit B. All payments due to TSRI by
Sponsor shall be payable in U.S. Dollars in quarterly installments in advance, within [...***...] of the dates set forth in the following payment schedule: 
  

							
	 1st payment:
	    	 due: [.***.]
	  		  	 amount (USD): $[.***.]

	 2nd payment:
	    	 due: [.***.]
	  		  	 amount (USD): $[.***.]

	 3rd payment:
	    	 due: [.***.]
	  		  	 amount (USD): $[.***.]

	 4th payment:
	    	 due: [.***.]
	  		  	 amount (USD): $[.***.]

 The amounts specified above include all expense, overhead and other related costs due by Sponsor to TSRI in connection
with the Research Program, and no other amounts shall be due or payable by Sponsor to TSRI or the Principal Investigator for performance of the Research Program. Each payment must reference the Research Project title, Agreement Number and Principal
Investigator for purposes of identification. Payments under this Section 2.4.a shall be sent to: 
 The Scripps Research
Institute 
 10550 North Torrey Pines Road, TPC-7 

La Jolla, California 92037 

Attn: Vice President, Sponsored Programs 

Fax No.: (858) 784-8037 

  
 ***Confidential
Treatment Requested 
 -4- 

 With a copy of Sponsor’s notice of payment or other accompanying correspondence
to:     
 The Scripps Research Institute 

10550 North Torrey Pines Road, TPC-9 

La Jolla, California 92037 

Attn: Director, Technology Development 

Fax No.: (858) 784-9910 

TSRI shall not be obligated to perform any of the research specified herein or to take any other action required under this Agreement if the funding is
not provided as set forth in Exhibit B and in accordance with the payment schedule as set forth in this Section 2.4.a. Furthermore, should Sponsor fail to make the first payment to TSRI in accordance with this Section 2.4.a., TSRI
shall have the right to immediately terminate this Agreement and this Agreement shall be null and void ab initio. 

  b.        Capital Equipment.    Equipment purchased by
TSRI with funds provided by Sponsor shall be the property of TSRI. All capital equipment provided under this Agreement by Sponsor for the use of TSRI remains the property of the Sponsor unless other disposition is mutually agreed upon in writing by
the Parties. If title to this equipment remains with the Sponsor, Sponsor is responsible for maintenance and repair of the equipment, insuring the equipment against damage or loss, and the costs of its transportation to and from the site where it
will be used. 
   c.        Indirect Cost
Adjustment.    TSRI shall have the right to adjust the payment amounts referenced above to reflect changes in the indirect cost rate negotiated between TSRI and the U.S. Government and that will be in effect during the
quarter that the work is performed. TSRI will notify Sponsor in writing of any change in the indirect cost rate before the effective date of such change. The corresponding direct costs will remain fixed as specified in Exhibit B. 

3.        OPTION FOR LICENSE. 

Notwithstanding the provisions of Sections 3.1 through 3.6 or any other provision of this Agreement to the contrary, TSRI and Sponsor agree that
the Patent Rights and Technology (including, without limitation, Joint Technology) are exclusively licensed to Sponsor, together with the Existing Technology, pursuant to the Exclusive License Agreement on the terms and conditions set forth therein.
For so long as the Exclusive License Agreement remains in effect: (a) all Patent Rights and Technology (including, without limitation, Joint Technology) arising under this Agreement are automatically deemed included in the subject matter
exclusively licensed to Sponsor under the Exclusive License Agreement, effective upon Sponsor’s delivery of written notice to TSRI pursuant to the first sentence of Section 3.4, and without any other action on the part of either party
pursuant to Section 3.3, 3.4 or 3.6 or otherwise; (b) Section 3.2 hereof shall continue in full force and effect; and (c) preparation, filing, 

  
 -5- 

 
prosecution and maintenance of Patent Rights shall be governed by the Exclusive License Agreement (and not Section 3.5 hereof). 

3.1      Grant of Option. Subject to the terms of this Agreement and the reservation of rights
specified in Sections 4.2 and 4.3, TSRI hereby grants to Sponsor: 

  a.        an exclusive option (the “Option”) to acquire an exclusive,
worldwide license, including the right to sublicense, under TSRI’s rights in the Patent Rights and/or Biological Materials, to make, have made, use, offer for sale, sell, have sold and import products, processes and Biological Material in the
Field. In the event that a product or process utilizes a Research Tool, such Research Tool shall be made available to Sponsor solely on a non-exclusive basis. 

  b.        a non-exclusive, royalty-free, non-transferable license to make and use Technology solely for Sponsor’s internal research purposes during the performance of the Research Program. Any transfer of materials to Sponsor under this
Section 3.1(b) shall require the execution of a Material Transfer Agreement. The terms of such Material Transfer Agreement shall be materially consistent with the form Material Transfer Agreement attached hereto as Exhibit C. 

3.2      Disclosure of Technology. After Principal Investigator submits an invention disclosure
covering any Technology to TSRI’s Office of Technology Development, TSRI shall disclose such Technology in writing to Sponsor (the “Technology Disclosure”). TSRI shall use reasonable efforts to provide a Technology Disclosure that
contains sufficient detail to (i) enable both parties to determine whether or not the particular Technology is TSRI Technology or Joint Technology; and (ii) enable Sponsor to appreciate the significance of such Technology and to evaluate
the advisability of exercising the option granted hereunder with respect to such Technology. All such Technology Disclosures shall be maintained in confidence by Sponsor. 

3.3      Option. Sponsor shall have a period of [...***...] from receipt of the Technology
Disclosure from TSRI (“Option Period”), within which to exercise its Option with respect to the particular Technology disclosed therein. 

3.4      Exercise of Option. Sponsor shall exercise its Option by delivering to TSRI a written
notice within the Option Period which specifies the particular Technology for which the Option is being exercised. Upon such notification, Sponsor and TSRI shall have a period of [...***...] within which to negotiate a definitive license
agreement. 

3.5                         
                   Patent Filings. TSRI shall direct and control the preparation, filing and prosecution of patent applications and patents within
the Patent Rights. As consideration for the Option, [...***...]. Payment shall be made within [...***...] 

  
 ***Confidential
Treatment Requested 
 -6- 

 
[...***...] after Sponsor receives an invoice therefor. Failure of Sponsor to pay patent fees and expenses as set forth above shall immediately relieve TSRI from its obligation to incur any
further patent fees and expenses. Sponsor’s obligation to [...***...] shall survive the termination or expiration of this Agreement. Both parties hereto agree that TSRI may, at its sole discretion, utilize TSRI’s Office of Patent
Counsel in lieu of or in addition to independent counsel for patent prosecution and maintenance of patent application(s). Sponsor shall have full rights of consultation with the patent attorney so selected on all matters relating to patent
application(s). 
 3.6      Joint Technology. The parties hereby agree that in the event that
the disclosed Technology is Joint Technology and Sponsor neither exercises its Option to such Joint Technology nor has a license to such Joint Technology under the Exclusive License Agreement (i.e., if the Exclusive License Agreement has
terminated), both Parties shall (i) have no further obligations to each other with respect to such Joint Technology and any resulting Patent Rights; and (ii) be free to independently license or otherwise dispose of their rights to such
Joint Technology and any resulting Patent Rights on a worldwide basis without accounting to the other Party. 

4.        INTERESTS AND RIGHTS IN INTELLECTUAL PROPERTY. 

4.1      Title. TSRI shall retain sole ownership and title to TSRI Technology and to all
intellectual property rights related thereto. TSRI shall, in the good faith exercise of its discretion, undertake reasonable efforts to preserve and maintain its ownership and title as TSRI deems appropriate. Ownership of and title to Joint
Technology shall be vested jointly in TSRI and Sponsor, with each owning an undivided interest therein. 

4.2      Governmental Interest. TSRI and Sponsor acknowledge that TSRI has received, and expects
to continue to receive, funding from the United States Government in support of TSRI’s research activities. TSRI and Sponsor acknowledge and agree that their respective rights and obligations pursuant to this Agreement shall be subject to the
rights of the United States Government, existing and as amended, which may arise or result from TSRI’s receipt of research support from the United States Government, including but not limited to, 37 CFR 401, the NIH Grants Policy Statement and
the NIH Guidelines for Obtaining and Disseminating Biomedical Research Resources. 

4.3      Reservation of Rights. TSRI reserves the right to [...***...]. In addition, TSRI
reserves the right to [...***...]. TSRI shall have no obligation to notify or inform Sponsor of such use or licenses. 

  
 ***Confidential
Treatment Requested 
 -7- 

 5.        CONFIDENTIALITY AND
PUBLICATION. 
 5.1      Treatment of Confidential Information. The parties agree that
during [...***...] of this Agreement, the receiving party will (a) maintain in confidence all Confidential Information to the same extent the receiving party maintains its own proprietary information; (b) not disclose such
Confidential Information to any third party without the prior written consent of the disclosing party; and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (and, if and to the extent applicable,
the Exclusive License Agreement). 
 If the receiving party is required to disclose Confidential Information by law or court order, the receiving
party shall limit the same to the minimum required to comply with the law or court order; provided that, prior to making such disclosure the receiving party shall notify the disclosing party, not later than [...***...] (or such shorter period
of time as may be reasonably practicable under the circumstances) before the disclosure, and shall, at the disclosing party’s request and expense, cooperate with the Disclosing Party’s efforts to seek confidential treatment of the
Confidential Information to be disclosed and/or to obtain a protective or other order, including extensions of time and the like, with respect to such disclosure. 

5.2      Publications. Sponsor acknowledges that it is the general policy of TSRI to encourage
publication of research results in technical or scientific journals; and Sponsor agrees that TSRI shall have a right to publish in accordance with its general policy. TSRI shall submit to Sponsor copies of proposed publications which describe
Technology and afford Sponsor a period of [...***...] to review the publication to (i) ascertain whether Sponsor’s Confidential Information would be disclosed by the publication; and (ii) ascertain whether or not submission or
presentation of the publication would preclude the parties from obtaining patent rights claiming Technology disclosed therein unless an application is filed with relevant patent authorities. If such publication discloses Sponsor’s Confidential
Information and upon Sponsor’s written request, TSRI shall remove such Confidential Information or delay publication for up to an additional [...***...] to allow Sponsor to protect its Confidential Information by filing a patent
application(s). In the event that Sponsor identifies any potentially patentable Technology with respect to which it wishes to file, or have TSRI file (as applicable), patent application(s), Sponsor shall notify TSRI of such in writing. Upon such
notification, TSRI shall, at its option, either delete the enabling portion of the proposed publication or presentation, or withhold publication or delay presentation for up to an additional [...***...] to allow filing of patent
application(s). Absent receipt by TSRI of any written instruction by Sponsor within the [...***...] period, TSRI shall be free to publish the proposed publication. 

5.3      Publicity. Except as otherwise provided herein or required by law, no party shall
originate any publication, news release or other public announcement, written or oral, whether in the public press, stockholders’ reports, or otherwise, relating to this 

  
 ***Confidential
Treatment Requested 
 -8- 

 
Agreement or to the performance hereunder without the prior written approval of the other party, which approval shall not be unreasonably withheld. Scientific publications published in accordance
with Section 5.2 of this Agreement shall not be construed as publicity governed by this Section 5.3. 

6.        WARRANTIES. 

6.1      Limited Warranty. TSRI hereby represents and warrants that it has full right and power to
enter into this Agreement. TSRI MAKES NO OTHER WARRANTIES CONCERNING PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS, BIOLOGICAL MATERIALS OR ANY OTHER MATTER WHATSOEVER, INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND TSRI DISCLAIMS ALL SUCH EXPRESS OR IMPLIED
WARRANTIES. TSRI MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF PATENT RIGHTS, OR THAT ANY PRODUCT, PROCESS, SERVICE, BIOLOGICAL MATERIAL, OR RESEARCH TOOL WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING UPON ANY PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS OR BIOLOGICAL MATERIALS COVERED BY THIS AGREEMENT. FURTHER, TSRI HAS MADE NO INVESTIGATION AND
MAKES NO REPRESENTATION THAT THE PATENT RIGHTS, RESEARCH TOOLS OR BIOLOGICAL MATERIALS ARE SUITABLE FOR SPONSOR’S PURPOSES. 
 IN NO EVENT SHALL
EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR
PROPERTY) ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER. TSRI’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF ANY KIND RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY SPONSOR TO
TSRI UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO NEGLIGENCE OR STRICT LIABILITY), OR
ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES FURTHER AGREE THAT EACH WARRANTY DISCLAIMER, EXCLUSION
OF DAMAGES OR OTHER LIMITATION OF LIABILITY HEREIN IS INTENDED TO BE SEVERABLE AND INDEPENDENT OF THE OTHER PROVISIONS SINCE THEY EACH REPRESENT SEPARATE ELEMENTS OF RISK ALLOCATION BETWEEN THE PARTIES. 

7.        TERM AND TERMINATION. 

7.1      Term. Unless terminated sooner, the initial term of this Agreement shall commence on the
Effective Date and shall continue until the earlier of (a) the 

  
 -9- 

 first (1st) anniversary of the Effective
Date, and (b) the completion of the Research Program, unless extended by written mutual agreement of the parties. 

7.2      Termination by Mutual Agreement.     This Agreement may be terminated
at any time upon the mutual written agreement of the parties. In the absence of an agreement to the contrary, no such termination shall have the effect of relieving Sponsor of its monetary obligations to fund the Research Program which shall have
accrued up and to the date of such termination. 
 7.3      Termination Upon Default. Except as
specified in Section 7.4, the failure of a party to perform any obligation required of it to be performed hereunder and the failure to cure within sixty (60) days (or, in the case of any failure by Sponsor to make any payment hereunder
when due, within thirty (30) days) after receipt of notice from the other party specifying in reasonable detail the nature of such default, shall constitute an event of default hereunder. Upon the occurrence of an event of default which is not
cured within the applicable notice period, the non-defaulting party may deliver to the defaulting party written notice of intent to terminate, such termination to be effective upon the date set forth in such
notice. Such termination rights shall be in addition to and not in substitution for any other remedies that may be available to the non-defaulting party serving such notice against the defaulting party.
Termination pursuant to this Section 7.3 shall not relieve the defaulting party of liability and damages to the non-defaulting party for breach of this Agreement. Waiver by any party of a single default
or a succession of defaults shall not deprive such party of any right to terminate this Agreement arising by reason of any subsequent default. 

7.4      Termination Upon Insolvency.     This Agreement may be terminated by a
party upon written notice of termination to the other party (“Insolvent Party”) in the event of the filing of bankruptcy by the Insolvent Party, or the appointment of a receiver of any of the Insolvent Party’s assets, or the making by
the Insolvent Party of any assignment for the benefit of creditors, or the institution of any involuntary bankruptcy proceedings against the Insolvent Party under any bankruptcy law that are not dismissed within sixty (60) days after
institution. Termination shall be effective upon the date specified in this notice. 

7.5      Effect of Expiration or Termination. 

  a.        Termination Upon Default of Sponsor.     Upon
the termination of this Agreement by reason of a default by Sponsor, neither party shall have any further rights or obligations with respect to this Agreement, other than the rights and obligations of the parties that accrued prior to the effective
date of such termination (including, without limitation, the obligation of Sponsor to make any and all final payments accrued prior to the date of termination and the obligation of the parties to make all reports required hereunder), and except as
provided below. Upon such termination of this Agreement, the parties shall continue to abide by their non-disclosure obligations as described in Section 5.1 and each party hereto shall fulfill any other
obligations incurred prior to such termination. Any such termination of this Agreement shall not constitute the termination of any license or any other agreements between the parties which are then in effect (such as, but not limited to, the 

  
 -10- 

 
Exclusive License Agreement) except as expressly provided therein. In addition, upon such termination, Sponsor’s Option under Section 3.1 shall be deemed automatically cancelled, and
Sections 4, 6, 7, 8 and 9 shall survive any such termination. 

  b.        Expiration or Termination upon Default of TSRI. Upon the
expiration of this Agreement at its regularly scheduled expiration date, or upon a termination of this Agreement on account of a default by TSRI, then TSRI shall make the disclosures required by Section 3.2 for Technology conceived or reduced
to practice up to the date of said expiration or termination; Sponsor shall have the right to exercise its option with respect to said Technology in accordance with the schedule and procedures specified in Sections 3.3 and 3.4 above; and any non-exclusive licenses that have been granted under Section 3.1 shall survive. Additionally, each party shall perform all other obligations up to the date of said expiration or termination; the parties shall
continue to abide by their non-disclosure obligations described in Section 5.1; and any previously existing license agreements or other agreements between the parties (such as, but not limited to, the
Exclusive License Agreement) shall continue in effect. No such expiration or termination of this Agreement shall affect the rights and obligations of the parties that accrued prior to the effective date of such expiration or termination. In
addition, upon such expiration or termination, Sections 4, 6, 7, 8 and 9 shall survive. 

8.        ASSIGNMENT; SUCCESSORS. 

8.1      Assignment. Any and all assignments of this Agreement or any rights granted hereunder by
Sponsor without the prior written consent of TSRI are void, except that, without the prior written consent of TSRI, (a) Sponsor may assign this Agreement and its rights and obligations hereunder to an Affiliate of Sponsor; and (b) Sponsor
may assign this Agreement and its rights and obligations hereunder in connection with the transfer or sale of all or substantially all of Sponsor’s business or assets to which this Agreement relates to a third party, whether by merger, sale of
stock, sale of assets or otherwise, subject to Section 8.2 hereof. 
 8.2      Binding Upon
Successors and Assigns.   Subject to the limitations on assignment set forth herein, this Agreement shall be binding upon and inure to the benefit of any successors in interest and assigns of TSRI and Sponsor. Any such successor to or
assignee of a party’s interest shall expressly assume in writing the performance of all the terms and conditions of this Agreement to be performed by such party and such written assumption shall be delivered to the other Party. 

9.        GENERAL PROVISIONS. 

9.1      Independent Contractors.     The relationship between TSRI and
Sponsor is that of independent contractors. TSRI and Sponsor are not joint venturers, partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent contracting parties. TSRI and
Sponsor shall have no power to bind or obligate each other in any manner, other than as is expressly set forth in this Agreement. 

  
 -11- 

 9.2      Arbitration. Any controversy or claim
arising out of or relating to this Agreement, or the breach thereof, shall be settled by binding confidential arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA”), and the
procedures set forth below. In the event of any inconsistency between the Rules of AAA and the procedures set forth below, the procedures set forth below shall control. Judgment upon the award rendered by the arbitrators may be enforced in any court
having jurisdiction thereof. 
   a.        Location.   The
location of the arbitration shall be in the County of San Diego. TSRI and Sponsor hereby irrevocably submit to the exclusive jurisdiction and venue of the American Arbitration Association arbitration panel selected by the parties and located in San
Diego County, California for any dispute regarding this Agreement, and to the exclusive jurisdiction and venue of the federal and state courts located in San Diego County, California for any action or proceeding to enforce an arbitration award or as
otherwise provided in Section 9.2 e below, and waive any right to contest or otherwise object to such jurisdiction or venue. 

  b.        Selection of Arbitrators.       The
arbitration shall be conducted by a panel of three neutral arbitrators who are independent and disinterested with respect to the parties, this Agreement, and the outcome of the arbitration. Each party shall appoint one neutral arbitrator, and these
two arbitrators so selected by the parties shall then select the third arbitrator, and all arbitrators must have at least ten (10) years experience in mediating or arbitrating cases regarding the same or substantially similar subject matter as
the dispute between TSRI and Sponsor. If one party has given written notice to the other party as to the identity of the arbitrator appointed by the party, and the party thereafter makes a written demand on the other party to appoint its designated
arbitrator within the next ten days, and the other party fails to appoint its designated arbitrator within ten days after receiving said written demand, then the arbitrator who has already been designated shall appoint the other two arbitrators.

   c.        Discovery. The arbitrators shall decide any disputes and
shall control the process concerning these pre-hearing discovery matters. Pursuant to the Rules of AAA, the parties may subpoena witnesses and documents for presentation at the hearing. 

  d.        Case Management. Prompt resolution of any dispute is important to
both parties; and the parties agree that the arbitration of any dispute shall be conducted expeditiously. The arbitrators are instructed and directed to assume case management initiative and control over the arbitration process (including scheduling
of events, pre-hearing discovery and activities, and the conduct of the hearing), in order to complete the arbitration as expeditiously as is reasonably practical for obtaining a just resolution of the
dispute. 

e.                         
                                Remedies.     The arbitrators
may grant any legal or equitable remedy or relief that the arbitrators deem just and equitable, to the same extent that 

  
 -12- 

 remedies or relief could be granted by a state or federal court, provided however, that no punitive
damages may be awarded. No court action shall be maintained seeking punitive damages. The decision of any two of the three arbitrators appointed shall be binding upon the parties. Notwithstanding anything to the contrary in this Agreement, prior to
or while an arbitration proceeding is pending, either party has the right to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce that party’s rights hereunder. In addition, no claim, dispute
or controversy that concerns the validity, enforceability, scope or infringement of a patent, trademark or copyright shall be subject to arbitration or any other provision of this Section 9.2. 

  f.        Expenses. The expenses of the arbitration, including the
arbitrators’ fees, expert witness fees, and attorney’s fees, may be awarded to the prevailing party, in the discretion of the arbitrators, or may be apportioned between the parties in any manner deemed appropriate by the arbitrators.
Unless and until the arbitrators decide that one party is to pay for all (or a share) of such expenses, both parties shall share equally in the payment of the arbitrators’ fees as and when billed by the arbitrators. 

  g.        Confidentiality. Except as set forth below and as necessary to
obtain or enforce a judgment upon any arbitration award, the parties shall keep confidential the fact of the arbitration, the dispute being arbitrated, and the decision of the arbitrators. Notwithstanding the foregoing, the parties may disclose
information about the arbitration to persons who have a need to know, such as directors, trustees, management employees, witnesses, experts, investors, attorneys, lenders, insurers, and others who may be directly affected. Additionally, if a party
has stock which is publicly traded, the party may make such disclosures as are required by applicable securities laws, but will use commercially reasonably efforts to seek confidential treatment for such disclosure. 

9.3      Entire Agreement; Modification.     This Agreement and all of the
attached Exhibits set forth the entire agreement and understanding between the parties as to the subject matter hereof, and supersede all prior or contemporaneous written or oral agreements, excluding the Exclusive License Agreement. There shall be
no amendments or modifications to this Agreement, except by a written document which is signed by both parties. 

9.4      California Law.     This Agreement shall be construed and enforced in
accordance with the laws of the State of California notwithstanding any conflicts or choice of laws provisions. 

9.5      No Use of Name.     The use of the name “The Scripps Research
Institute”, “Scripps”, “TSRI” or any variation thereof in connection with the advertising, sale or performance of products, processes, services, Biological Materials or Research Tools is expressly prohibited. 

9.6      Headings.     The headings for each article and section in this
Agreement have been inserted for the convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular article or section. 

  
 -13- 

 9.7        Severability.
  Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining
provisions thereof. The parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by them when entering this Agreement may be realized. 

9.8        No Waiver.   Any delay in enforcing a party’s rights under
this Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver
as to a particular matter for a particular period of time. 
 9.9        Notices. Any
notices required by this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier,
postage prepaid, and shall be forwarded to the respective addresses set forth below unless subsequently changed by written notice to the other party: 
  

			
	 FOR TSRI:
	  	 The Scripps Research Institute

		  	 10550 North Torrey Pines Road, TPC-9

		  	 La Jolla, California 92037

		  	 Attn: Vice President, Business Development

		  	 Fax No.: (858) 784-9910

		
	 With a copy to:
	  	 The Scripps Research Institute

		  	 10550 North Torrey Pines Road, TPC-8

		  	 La Jolla, California 92037

		  	 Attention: Chief Business Counsel

		  	 Fax No.: (858) 784-9910

		
	 FOR SPONSOR:
	  	 Synthorx, Inc.

		  	 11099 North Torrey Pines Road, Suite 290

		  	 La Jolla, California 92037

		  	 Attn: President and Chief Executive Officer

		  	 Fax No.: (858) 750-4701

 Notices shall be deemed delivered upon the earlier of (i) when received; (ii) three (3) days after
deposit into the U.S. mail; (iii) the date notice is sent via telefax, telex or cable; or (iv) the day immediately following delivery to an overnight courier guaranteeing next-day delivery (except
Sunday and holidays). 
 9.10    Compliance with U.S. Laws. Nothing contained in this Agreement shall
require or permit TSRI or Sponsor to do any act inconsistent with the requirements of any 

  
 -14- 

 
United States law, regulation or executive order as the same may be in effect from time to time. 

9.11        Indemnity.     Sponsor shall indemnify, defend (by
counsel reasonably acceptable to TSRI) and hold harmless TSRI and any parent, subsidiary or other affiliated entity of TSRI and their trustees, directors, officers, employees, scientists, agents, successors, assigns and other representatives
(collectively, the “Indemnitees”) from and against all claims, suits, actions, damages, liabilities, losses and other expenses, including without limitation reasonable attorney’s fees, expert witness fees and costs incurred by or
asserted against the Indemnitees, whether or not a lawsuit or other proceeding is filed (collectively “Claim”), that arise out of or relate to any third party allegations or suits regarding Sponsor’s use of the Technology or the
exercise of its non-exclusive license rights under Section 3.1.b. Sponsor shall not enter into any settlement of such Claims that imposes any obligation on TSRI, that does not unconditionally release TSRI
from all liability or that would have an adverse effect on TSRI’s reputation or business without TSRI’s prior written consent. In the event an Indemnitee seeks indemnification with respect to a Claim under this Section 9.11, it shall
notify Sponsor in writing of such Claim as soon as reasonably practicable after it receives notice of such Claim, shall permit Sponsor to assume direction and control of the defense of the Claim (including the right to settle the Claim solely for
monetary consideration, subject to the limitations of the preceding sentence) using counsel selected by Sponsor and reasonably acceptable to TSRI, and shall cooperate as reasonably requested (at the expense of Sponsor) in the defense of the Claim.
Notwithstanding the above, Indemnitees, [...***...], shall have the right to retain separate independent counsel to assist in defending any such Claims. In the event Sponsor fails to promptly indemnify and defend such Claims and/or pay
Indemnitees’ expenses as provided above, Indemnitees shall have the right to defend themselves, and in that case, [...***...] of each of Indemnitees’ written requests. This indemnity shall be a direct payment obligation and not
merely a reimbursement obligation of Sponsor to Indemnitees. 

  
 ***Confidential
Treatment Requested 
 -15- 

 IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized
representatives as of the date set forth above. 
  

					
	 TSRI:
	 		 	 SPONSOR:

			
	 THE SCRIPPS RESEARCH INSTITUTE
	 		 	 SYNTHORX, INC.

		
	 By: /s/
Scott Forrest                     
	 	 By:  /s/ Court
Turner                          

		
	 Title: VP, Business Development
	 	 Title: President and
CEO                   

  
 -16- 

 EXHIBIT A 

RESEARCH PROGRAM 
 Background

 [...***...] 

  
 ***Confidential
Treatment Requested 

 [...***...] 

Literature Cited 
  

	1.	 DA Malyshev, K Dhami, HT Quach, T Lavergne, P Ordoukhanian, A Torkamani, FE Romesberg. Efficient and
sequence-independent replication of DNA containing a third base pair establishes a functional six-letter genetic alphabet. (2012) Proc Natl Acad Sci USA, 109:12005-12010. PMCID: 3409741.

	2.	 YJ Seo, S Matsuda, FE Romesberg. Transcription of an expanded genetic alphabet. (2009) J Am Chem Soc,
131:5046-5047. PMCID: PMC2728119. 

	3.	 HH Winkler, HE Neuhaus. Non-mitochondrial ATP transport. (1999) Trends
Biochem Sci, 24:64-68. 

	4.	 H Amiri, O Karlberg, SG Andersson. Deep origin of plastid/parasite ATP/ADP translocases. (2003) J Mol Evol, 56:137-150. 

	5.	 TP Hatch, E Al-Hossainy, JA Silverman. Adenine nucleotide and lysine transport
in Chlamydia psittaci. (1982) J Bacteriol, 150:662-670. 

	6.	 HH Winkler. Rickettsial permeability: an ADP-ATP transport system.
(1976) J Biol Chem, 251:389-396. 

	7.	 M Horn, M Wagner. Bacterial endosymbionts of free-living amoebae. (2004) J Eukaryot Microbiol, 5:509-514. 

	8.	 I Haferkamp, S Schmitz-Esser, M Wagner, N Neigel, M Horn, HE Neuhaus. Tapping the nucleotide pool of the host: novel
nucleotide carrier proteins of Protochlamydia amoebophila. (2006) Mol Microbiol, 60:1534-1545. PMCID: 1513512. 

	9.	 B Miroux, JE Walker. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some
membrane proteins and globular proteins at high levels. (1996) J Mol Biol, 260:289-298. 

	10.	 I Haferkamp, N Linka. Functional expression and characterisation of membrane transport proteins. (2012) Plant
Biol, 14:675-690. 

	11.	 M Ast, A Gruber, S Schmitz-Esser, HE Neuhaus, PG Kroth, M Horn, I Haferkamp. Diatom plastids depend on nucleotide
import from the cytosol. (2009) Proc Natl Acad Sci USA, 106:3621-3626. PMCID: 2642474. 

  
 ***Confidential
Treatment Requested 

	12.	 T Lavergne, DA Malyshev, FE Romesberg. Major groove substituents and polymerase recognition of a class of
predominantly hydrophobic unnatural base pairs. (2012) Chem Eur J, 18:1231-1239. PMCID: 3693734. 

	13.	 L Li, M Degardin, T Lavergne, D Malyshev, K Dhami, P Ordoukhanian, FE Romesberg. Natural-like replication of an
unnatural base pair for the expansion of the genetic alphabet and biotechnology applications. (2014) J Am Chem Soc, 136:826-829. 

	14.	 H Hashimoto, JE Pais, X Zhang, L Saleh, Z-Q Fu, N Dai, IR Correa, Y Zheng, X
Cheng. Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA. (2014) Nature, 506:391-395.

	15.	 YJ Seo, DA Malyshev, T Lavergne, P Ordoukhanian, FE Romesberg. Site-specific labeling of DNA and RNA using an
efficiently replicated and transcribed class of unnatural base pairs. (2011) J Am Chem Soc, 133:19878-19888. 

	16.	 DA Malyshev, YJ Seo, P Ordoukhanian, FE Romesberg. PCR with an expanded genetic alphabet. (2009) J Am Chem Soc,
131:14620-14621. PMCID: 2978235. 

	17.	 I Hirao, M Kimoto, T Mitsui, T Fujiwara, R Kawai, A Sato, Y Harada, S Yokoyama. An unnatural hydrophobic base pair
system: site-specific incorporation of nucleotide analogs into DNA and RNA. (2006) Nat Methods, 3:729-735. 

	18.	 MF Goodman. Error-prone repair DNA polymerases in prokaryotes and eukaryotes. (2002) Annu Rev Biochem, 71:17-50. 

	19.	 J Samuelson. Bacterial Systems. In: AS Robinson, editor. Production of Membrane Proteins: Strategies for Expression
and Isolation: Wiley-VCH; 2011. p. 11-35. 

	20.	 MJ Giacalone, AM Gentile, BT Lovitt, NL Berkley, CW Gunderson, MW Surber. Toxic protein expression in Escherichia coli
using a rhamnose-based tightly regulated and tunable promoter system. (2006) Biotechniques, 40:355-364. 

	21.	 ST Cardona, CL Mueller, MA Valvano. Identification of essential operons with a rhamnose-inducible promoter in
Burkholderia cenocepacia. (2006) Appl Environ Microbiol, 72:2547-2555. PMCID: 1448982. 

	22.	 H Dong, W Tao, Y Zhang, Y Li. Development of an anhydrotetracycline-inducible gene expression system for
solvent-producing Clostridium acetobutylicum: A useful tool for strain engineering. (2012) Metab Eng, 14:59-67. 

	23.	 A Chatterjee, SB Sun, JL Furman, H Xiao, PG Schultz. A versatile platform for single- and multiple-unnatural amino
acid mutagenesis in Escherichia coli. (2013) Biochemistry, 52:1828-1837. PMCID: 3855549. 

	24.	 A Berlec, B Štrukelj. Current state and recent advances in biopharmaceutical production in Escherichia coli,
yeasts and mammalian cells. (2013) J Ind Microbiol Biotechnol, 40:257-274. 

	25.	 S Shao, RS Hegde. Membrane Protein Insertion at the Endoplasmic Reticulum. (2011) Annual Review of Cell and
Developmental Biology, 27:25-56. 

	26.	 A Idiris, H Tohda, H Kumagai, K Takegawa. Engineering of protein secretion in yeast: strategies and impact on protein
production. (2010) Appl Microbiol Biotechnol, 86:403-417. 

	27.	 P Malkus, F Jiang, R Schekman. Concentrative sorting of secretory cargo proteins into COPII-coated vesicles.
(2002) J Cell Biol, 159:915-921. PMCID: 2173974. 

	28.	 HB Parmar, C Barry, F Kai, R Duncan. Golgi complex-plasma membrane trafficking directed by an autonomous, tribasic
Golgi export signal. (2014) Mol Biol Cell, 25:866-878. PMCID: 3952855. 

	29.	 A Graf, M Dragosits, B Gasser, D Mattanovich. Yeast systems biotechnology for the production of heterologous proteins.
(2009) FEMS Yeast Res, 9:335-348. 

	30.	 M Delic, M Valli, AB Graf, M Pfeffer, D Mattanovich, B Gasser. The secretory pathway: exploring yeast diversity.
(2013) FEMS Microbiol Rev, 37:872-914. 

	31.	 C Da-Re, E Franzolin, A Biscontin, A Piazzesi, B Pacchioni, MC Gagliani, G
Mazzotta, C Tacchetti, MA Zordan, M Zeviani, P Bernardi, V Bianchi, C De Pitta, R Costa. Functional Characterization of drim2, the Drosophila melanogaster Homolog of the Yeast Mitochondrial Deoxynucleotide Transporter. (2014) J Biol Chem,
289:7448-7459. PMCID: 3953259. 

 EXHIBIT B 

BUDGET 
  

											
	 Principal Investigator/Program Director (Last, First, Middle):

 
	  	 Romesberg, Floyd
  
	 
	 
	 BUDGET

 
	  

	 	 	 
	
PERSONNEL (Applicant organization only)
	  	 %

 
	  	 	YEAR 1	 
	 NAME
	  	ROLE ON
PROJECT	  	 EFFORT  

ON  
 PROJ.  
	  	 
	        SALARY/
FRINGE	
 
	 Romesberg, Floyd
	  	
Principal
Investigator
  
	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	
Chin, Jodie
  
	  	 Research Scientist

 
	  	 [...***...]

 
	  	 	[...***...]	 
	 	 	 	 
	
Technician, TBN
  
	  	 Technician

 
	  	 [...***...]

 
	  	 	[...***...]	 
	
SUBTOTAL                

	  	 	[...***...]	 
	  EQUIPMENT 
(Itemize)
  
	  	 	 	 
	
 SUPPLIES  (Itemize by category)
	  	 	 	 
	
Bio/chemicals, molecular biology kits, enzymes, disposable plasticware (tubes, trays, pipette tips), bacterial and yeast growth media components

 
	  	 	[...***...]	 
	  TRAVEL

 
	  	 	 	 
	
 OTHER EXPENSES  (Itemize by category)
	  	 	 	 
	
DNA synthesis; DNA sequencing; Access fees for NMR and MS characterizations

 
	  	 	[...***...]	 
	 	 
	
 DIRECT COSTS
  
	  	$	[...***...]	 
	 	 
	
 INDIRECT COSTS @ [...***...]%

 
	  	$	[...***...]	 
	
 TOTAL COSTS  

 
  
	  	$	[...***...]	 

  
 ***Confidential
Treatment Requested 

 EXHIBIT C 

FORM OF MATERIAL TRANSFER AGREEMENT 
 THE
SCRIPPS RESEARCH INSTITUTE 
 MATERIAL TRANSFER AGREEMENT 

[Date] 
 [Contact’s Name] 

[Sponsor’s name] 
 [Sponsor’s Address] 

Dear Dr. [Contact’s Name]: 
 This is to
acknowledge your request for the [Materials Requested] to be provided by [Principal Investigator] at The Scripps Research Institute (TSRI) pursuant to Section 3.1.b of the Research Funding and Option Agreement between TSRI and [Sponsor’s
name] dated                                 . This material and all modifications
and derivatives of this material are referred to herein as “Materials”. 
 TSRI is pleased to cooperate with your use of these Materials at
[Sponsor’s name] for your scientific research. However, before forwarding them to you, TSRI needs [Sponsor’s name] to agree to the following terms and conditions: 

(1)    that TSRI hereby grants Sponsor a nonexclusive, royalty-free,
non-transferable license to make and use the Materials solely for your internal research purposes; 

(2)    that the Materials shall be received by [Sponsor’s name] only for use in scientific research in
[Sponsor’s name]’s laboratories and that all applicable guidelines set forth by the National Institutes of Health (NIH), U.S. Department of Agriculture (USDA) or other government agencies regarding the use of these Materials shall be
followed; 
 (3)    these Materials are provided as a service to the research community. THE MATERIALS ARE BEING
SUPPLIED TO YOU WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OF ANY KIND, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS
ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, ALL OF WHICH ARE DISCLAIMED BY TSRI 

 (4)    that [Sponsor’s name] shall bear all risk to
[Sponsor’s name] and/or any others resulting from any use, directly or indirectly, to which [Sponsor’s name] puts the Materials or any other materials that could not have been made but for these Materials; 

(5)    that [Sponsor’s name] hereby defends, indemnifies, and holds harmless TSRI, its affiliates, its
trustees, officers, employees and agents from any loss, claim, damage, or liability, of any kind whatsoever, including without limitation reasonable attorney’s fees, expert witness fees and costs, whether or not a lawsuit or other proceeding is
filed, which may arise from [Sponsor’s name]’s use, storage or disposal of the Materials or any other material that could not have been made but for the Materials, except to the extent such arise due to the gross negligence or willful
misconduct of TSRI; 
 (6)    that you provide us with your Federal Express account number or an account number
for another courier service, so that we may ship the Materials to you. 
 The Materials are to be used with caution and prudence in any experimental
work, since all of their characteristics are not known. Moreover, they are not to be used for testing in or treatment of humans. 
 If you agree to
accept these Materials under the above conditions, please sign the enclosed duplicate copy of this letter, have it signed by an authorized representative of [Sponsor’s name] and return one original to me. Upon receipt of that confirmation I
will forward the Materials to you. 
 THE SCRIPPS RESEARCH INSTITUTE 

 

	
	
	 Scott Forrest

	 Senior Director, Technology Development

	 [Date]

 ACCEPTED: 
  

					
	 Recipient’s Signature
	 		    	 Authorized Institutional Rep. Signature

			
		 		    	
	 Recipient’s Printed Name and Title
	 		    	 Authorized Rep. Printed Name and Title

			
		 		    	
	 Date
	 		    	 Date

 FIRST AMENDMENT to 

RESEARCH FUNDING AND OPTION AGREEMENT 

This First Amendment (“Amendment”) is entered into effective as of the last date set forth below and is made to RESEARCH FUNDING AND
OPTION AGREEMENT dated July 31, 2014 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and SYNTHORX, INC., a Delaware corporation
(“Sponsor”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement. 

WHEREAS, the Parties desire to make certain amendments to the Agreement under the terms and conditions contained herein; 

NOW, THEREFORE, the Parties agree to amend the Agreement as follows: 

 

	1	 Sponsor and TSRI agree Section 2.4 (a) of the Agreement shall be revised to add the following payments
to the payment schedule: 

							
		 	 5th payment:
	 	due: [...***...]	  	amount (USD): $[...***...]
		 	 6th payment:
	 	due: [...***...]	  	amount (USD): $[...***...]
		 	 7th payment:
	 	due: [...***...]	  	amount (USD): $[...***...]
		 	 8th payment:
	 	due: [...***...]	  	amount (USD): $[...***...]

  

	2.	 Exhibit B-2 below shall be added to Exhibit B and is hereby
incorporated by reference. 

  

	3.	 Section 7.1 shall be deleted in its entirety and replaces as follows:  

Term.       Unless terminated sooner, the initial term of this Agreement
shallcommence on the Effective Date and shall continue until the earlier of (a) thesecond (2nd) anniversary of the Effective Date, and (b) the completion of theResearch Program, unless
extended by written mutual agreement of the parties. 
  

	4.	 The Research Program in Exhibit A of the Agreement shall be expanded by the research described in Exhibit A-1 below. 

 Except as expressly set forth herein, all of the terms and provisions of
the Agreement shall remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly
authorized representatives as of the last date set forth below. 
  

									
	 TSRI:    
	 		 	Sponsor:                
	  
 THE SCRIPPS
RESEARCH INSTITUTE
	 		 	  
 SYNTHORX, INC.

			
		 		 	
	 By: /s/ Scott
Forrest                            
	 		 	By: /s/ Court
Turner                        
	             Scott
Forrest
	 		 	       Court Turner

			
	 Title: VP, Business Development
	 		 	Title: Chief Executive Officer
					
		 		 		 		 	
	 Date:
9/2/2015                                     
	 		 	Date:
9/2/2015                                

  
 ***Confidential
Treatment Requested 

 Exhibit A-1 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Exhibit B-2 

Synthorx 
 Principal
Investigator/Program Director (Last, First, Middle): Romesberg, Floyd 

 
  

BUDGET 
  

									
	 	 	 
	
PERSONNEL (Applicant organization only)
	  	 %

 
 EFFORT

 
 ON

 
	  	 	YEAR 2	 
	  

NAME
	  	 ROLE ON

 
 PROJECT
	  	   

	
            SALARY/             

FRINGE
	   

 

	 	 	 	 
	 Romesberg,
Floyd
	  	Principal	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 Chin,
Jodie
	  	Research Scientist	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 Technician,
TBN
	  	Technician	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 
	
SUBTOTAL   

	  	 	[...***...]	 
		 
	 EQUIPMENT (Itemize)

 
	  	 	 	 
		 
	 SUPPLIES (itemize by category)

 
 Bio/chemicals, molecular biology kits, enzymes, disposable plasticware (tubes,
trays, pipette tips), bacterial and yeast growth media components
  
	  	 

	

[...***...]	

 
		 
	 TRAVEL

 
	  	 	 	 
		 
	 OTHER EXPENSES (itemize by category)

 
 DNA synthesis; DNA sequencing; access fees for NMR and MS characterizations

 
	  	 

	

[...***...]	

 
				 
	 TOTAL COSTS   

  
	  	 	  	 	  	$	              [...***...]	 

  
 ***Confidential
Treatment Requested 

 SECOND AMENDMENT to 

RESEARCH FUNDING AND OPTION AGREEMENT 

This Second Amendment (“Amendment”) is entered into effective as of the last date set forth below and is made to RESEARCH FUNDING AND
OPTION AGREEMENT dated July 31, 2014 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and SYNTHORX, INC., a Delaware
corporation(“Sponsor”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement. 

WHEREAS, the Parties desire to make certain amendments to the Agreement (as amended) under the terms and conditions contained herein; 

NOW, THEREFORE, the Parties agree to amend the Agreement as follows: 
  

	1.	 Sponsor and TSRI agree Section 2.4 (a) of the Agreement shall be revised to add the following payments
to the payment schedule: 

  

							
		 	 9th payment:
	 	 due: [...***...]
	  	amount (USD): $[...***...]
		 	 10th payment:
	 	 due: [...***...]
	  	amount (USD): $[...***...]
		 	 11th payment:
	 	 due: [...***...]
	  	amount (USD): $[...***...]
		 	 12th payment:
	 	 due: [...***...]
	  	amount (USD): $[...***...]

  

	2.	 Exhibit B-2 below shall be added to Exhibit B and is hereby
incorporated by reference. 

  

	3.	 Section 7.1 shall be deleted in its entirety and replaces as follows: 

Term. Unless terminated sooner, the initial term of this Agreement shall commence on the Effective Date
and shall continue until the earlier of (a) the third (3rd) anniversary of the Effective Date, and (b) the completion of the Research Program, unless extended by written mutual agreement
of the parties. 
  

	4.	 The Research Program in Exhibit A of the Agreement shall be expanded by theresearch described in Exhibit A-1 below. 

 Except as expressly set forth herein, all of the terms and provisions of
the Agreement shall remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorized
representatives as of the last date set forth below. 
  

					
	 TSRI:
	 		  	 Sponsor.

			
	 THE SCRIPPS RESEARCH INSTITUTE
	 		  	 SYNTHORX, INC.

			
	 By: /s/ Julia
Roufer                                        
  
	 		  	 By: /s/ Court R.
Turner                                

		 		  	             Court R. Turner

	 Title:    Executive Director
	 		  	
	              Business Development
	 		  	 Title:  Chief Executive Officer

			
	
Date:    9/9/16                
                                    
	 		  	 Date:  
9/9/16                                        
       

  
 ***Confidential
Treatment Requested 

 Exhibit A-1 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Exhibit B-2 

Synthorx 
 Principal
Investigator/Program Director (Last, First, Middle): Romesberg, Floyd 

 
  

BUDGET 
  

									
	 	 	 
	 PERSONNEL (Applicant organization only)
	  	 %

 
 EFFORT

 
 ON

 
	  	 	YEAR 2	 
	  

NAME
	  	  

ROLE ON
  

PROJECT
  
	  	 
 
	            SALARY/         
   
 FRINGE
	 

 

	
Romesberg, Floyd
	  	Principal	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 Chin,
Jodie
	  	Research Scientist	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 Technician,
TBN
	  	Technician	  	[...***...]	  	 	[...***...]	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 
	
SUBTOTAL  

	  	 	[...***...]	 
		 
	 EQUIPMENT (Itemize)

 
	  	 	 	 
		 
	 SUPPLIES (Itemize by category)

 
 Bio/chemicals, molecular biology kits, enzymes, disposable plasticware (tubes,
trays, pipette tips), bacterial and yeast growth media components
  
	  	 	[...***...]	 
		 
	 TRAVEL

 
	  	 	 	 
		 
	 OTHER EXPENSES (Itemize by category)

 
 DNA synthesis; DNA sequencing; access fees for NMR and MS
characterizations
  
  
	  	 	[...***...]	 
				 
	   TOTAL COSTS  

	  	 	  	 	  	 	$[...***...]	 

  
 ***Confidential
Treatment Requested 

 CONFIDENTIAL 
  

 THIRD AMENDMENT to 

RESEARCH FUNDING AND OPTION AGREEMENT 

This third Amendment (“Third Amendment”), entered into and made effective as of the last dated signature below, is made to RESEARCH
FUNDING AND OPTION AGREEMENT dated July 31st, 2014 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and SYNTHORX, INC., a Delaware corporation
(“Sponsor”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement. 
 WHEREAS,
the Parties desire to make certain amendments to the Agreement (as amended) under the terms and conditions contained herein; 
 NOW,
THEREFORE, the Parties agree to amend the Agreement as follows: 
  

	1	 Section 1.2 of the Agreement shall be deleted in its entirety and replaced as follows:

  

	 	1.2	 Agreement Number. The original Agreement has been assigned TSRI agreement number 2014-0475, the first
amendment has been assigned TSRI agreement number 2015-0949, the second amendment has been assigned TSRI agreement number 2016-0927, and this Third Amendment has been assigned TSRI agreement number 2017-0685. 

 

	2.	 In accordance with Exhibit B-1 and with the preceding amendments
referenced above, Section 2.4 (a) of the Agreement shall be revised to add the following payments to the payment schedule: 

  

							
		 	 13th payment:
	  	due: [...***...]	  	amount (USD): $[...***...]
		 	 14th payment:
	  	due: [...***...]	  	amount (USD): $[...***...]
		 	 15th payment:
	  	due: [...***...]	  	amount (USD): $[...***...]
		 	 16th payment:
	  	due: [...***...]	  	amount (USD): $[...***...]

  

	3.	 Exhibit B-2 below shall be added to Exhibit B and is hereby
incorporated by reference. 

  

	4.	 Section 7.1 shall be deleted in its entirety and replaced as follows: 

 

	 	7.1	 Term. Unless terminated sooner, the initial term of this Agreement shall commence on the Effective
Date and shall continue until the earlier of (a) the fourth (4th) anniversary of the Effective Date, and (b) the completion of the Research Program, unless extended by written mutual agreement of the parties. 

 

	5.	 The Research Program in Exhibit A of the Agreement shall be expanded by the research described in Exhibit A-1 below. 

 Except as expressly set forth herein, all of the terms and provisions of
the Agreement shall remain in full force and effect. 
 IN WITNESS WHEREOF, the Parties have executed this Third Amendment by their duly
authorized representatives as of the last date set forth below. 

  
 ***Confidential
Treatment Requested 
 Page 1 of 6 

 CONFIDENTIAL 
  

									
	 TSRI:
	 		 	Sponsor:                
			
	 THE SCRIPPS RESEARCH INSTITUTE
	 		 	SYNTHORX, INC.
			
	 By: /s/ Matt Tremblay
                                    
	 		 	By: /s/ Tighe
Reardon                                
	
                   
       Matt Tremblay
	 		 	
                      Tighe
Reardon

			
	 Title: VP, Business Development
	 		 	Title: Chief Financial Officer
		 		 		 		 	
	 Date: October 16, 2017
                                         
 
	 		 	Date: October 6, 2017
                                    

  
 Page 2 of 6 

 CONFIDENTIAL 
  

 Exhibit A-1 

[...***...] 

  
 ***Confidential
Treatment Requested 
 Page 3 of 6 

 CONFIDENTIAL 
  

 Exhibit B-1 

Synthorx 
 Principal
Investigator/Program Director (Last, First, Middle): Romesberg, Floyd 

 
  

BUDGET 
  

									
	 	 	 
	
PERSONNEL (Applicant organization only)
	  	 %

 
 EFFORT

 
 ON

 
	  	 	YEAR 2	 
	  

NAME
	  	 ROLE ON

 
 PROJECT
	  	   

	 SALARY/ 

FRINGE
	   

 

	
Romesberg, Floyd
	  	  

Principal
	  	[...***...]	  	 	[...***...]	 
	
Chin, Jodie
	  	  

Research Scientist
	  	[...***...]	  	 	[...***...]	 
	
Technician, TBN
	  	  

Technician
	  	[...***...]	  	 	[...***...]	 
	 	  	 	  	 	  	 	 	 
	 	  	 	  	 	  	 	 	 
	 	  	 	  	 	  	 	 	 
	 	  	 	  	 	  	 	 	 
	 	 
	
      SUBTOTAL   

	  	   
	 [...***...] 
	   

		 
	 EQUIPMENT (Itemize)

 
	  	 	 	 
		 
	 SUPPLIES (itemize by category)

 
 Bio/chemicals, molecular biology kits, enzymes, disposable plasticware
(tubes, trays, pipette tips), bacterial and yeast growth media components
	  	 

  
	

 [...***...] 
	

   

		 
	 TRAVEL

 
	  	 	 	 
	 	 
	 OTHER EXPENSES (itemize by category)

 
 DNA synthesis; DNA sequencing; access fees for NMR and MS characterizations

 
	  	 

	

[...***...]	

 
				 
	  DIRECT COSTS

 
	  	 	  	 	  	 	$        [...***...]	 
				 
	  INDIRECT COSTS @ [...***...] %

 
	  	 	  	 	  	 	$        [...***...]	 
				 
	  TOTAL COSTS  

  
	  	 	  	 	  	 	$        [...***...]	 

  
 ***Confidential
Treatment Requested 
 Page 6 of 6 

 FOURTH AMENDMENT 

to 
 RESEARCH FUNDING AND OPTION
AGREEMENT 
 This Fourth Amendment (“Fourth Amendment”), entered into and made effective as of the last dated signature below, is made to RESEARCH
FUNDING AND OPTION AGREEMENT dated July 31st, 2014 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and SYNTHORX, INC., a Delaware corporation
(“Sponsor”). Capitalized terms used but not defined herein shall have the same meanings set forth in the Agreement. 
 WHEREAS, the Parties desire
to make certain amendments to the Agreement (as amended) under the terms and conditions contained herein; 
 NOW, THEREFORE, the Parties agree to amend the
Agreement as follows: 
  

	1.	 Section 1.2 of the Agreement shall be deleted in its entirety and replaced as follows: 

 

	 	1.2	 Agreement Number. The original Agreement has been assigned TSRI agreement number 2014-0475, the first amendment
has been assigned TSRI agreement number 2015-0949, the second amendment has been assigned TSRI agreement number 2016-0927, the Third Amendment has been assigned TSRI agreement number 2017-0685, and this Fourth Amendment has been assigned TSRI
agreement number 2018-0769. 

  

	2.	 In accordance with Exhibit B-1 and with the preceding amendments
referenced above, Section 2.4 (a) of the Agreement shall be revised to add the following payments to the payment schedule: 

  

							
		 	 17th payment:
	  	 due: [...***...]
	  	 amount (USD): $[...***...]

				
		 	 18th payment:
	  	 due: [...***...]
	  	 amount (USD): $[...***...]

				
		 	 19th payment:
	  	 due: [...***...]
	  	 amount (USD): $[...***...]

				
		 	 20th payment:
	  	 due: [...***...]
	  	 amount (USD): $[...***...]

  

	3.	 Exhibit B-1 below shall be added to Exhibit B and is hereby
incorporated by reference. 

  

	4.	 Section 7.1 shall be deleted in its entirety and replaced as follows: 

 

	 	7.1	 Term. Unless terminated sooner, the initial term of this Agreement shall commence on the Effective Date and
shall continue until the earlier of (a) the fifth (5th) anniversary of the Effective Date, and (b) the completion of the Research Program, unless extended by written mutual agreement of the parties. 

 

	5.	 The Research Program in Exhibit A of the Agreement shall be expanded by the research described in Exhibit A-1 below. 

  
 ***Confidential
Treatment Requested 

 Except as expressly set forth herein, all of the terms and provisions of the Agreement shall remain in full
force and effect. 
 In WITNESS WHEREOF, the Parties have executed this Fourth Amendment by their duly authorized representatives as of the last date set
forth below. 
  

			
	 TSRI:
	  	 Sponsor:

	 THE SCRIPPS RESEARCH INSTITUTE
	  	 SYNTHORX, INC.

		
	 By: /s/ Daniel
Catron                                        
 
	  	 By: /s/ Laura Shawver,
Ph.D.            

		
	 Name: Daniel Catron
	  	 Name: Laura Shawver, Ph.D.            

		
	 Title: Director, Office of Technology Development
	  	 Title: Chief Executive Officer           

		
	 Date:
8/16/2018                                        
         
	  	 Date:
8/16/2018                                 

 Exhibit A-1 

[...***...] 

  
 ***Confidential
Treatment Requested 

 Exhibit B-1 

Synthorx 
 Principal
Investigator/Program Director (Last, First, Middle):         Romesberg, Floyd 
  
  

BUDGET 
  

							
	 	 	 
	  

PERSONNEL (Applicant organization only)
	  	 %

 
 EFFORT
ON
PROJ.
	 	YEAR 1
	
NAME
	  	  
 ROLE
ON
PROJECT
	 	
            SALARY/            

FRINGE

	 Romesberg, Floyd
	  	Principal
Investigator	  	[...***...]	 	[...***...]
	 Chin, Jodie

 
	  	Research Scientist	  	[...***...]	 	[...***...]
	 Technician, TBN

 
	  	Technician	  	[...***...]	 	[...***...]
	  

SUBTOTAL  

  
	 	[...***...]
	  EQUIPMENT (Itemize)

 
	 	 
	
 SUPPLIES (Itemize by category)
	 	 
	
Bio/chemicals, molecular biology kits, enzymes, disposable plasticware (tubes, trays, pipette tips), bacterial and yeast growth media components

 
	 	[...***...]
	  TRAVEL

 
	 	 
	
 OTHER EXPENSES (Itemize by category)
	 	 
	
DNA synthesis, DNA sequencing, access fees for NMR and MS characterizations

 
	 	[...***...]
	  

 DIRECT COSTS
  
	 	$            
[...***...]
	  

 INDIRECT COSTS @ [...***...] %

 
	 	$           
 [...***...]
	  

 TOTAL COSTS  

  
	 	$           
 [...***...]

  
 ***Confidential Treatment
RequestedEX-10.7

 Exhibit 10.7 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(c) and Rule 406 of the 

Securities Act of 1933, as amended. 

SYNTHORX, INC. 
 MASTER
SERVICES AGREEMENT 
 THIS MASTER SERVICES
AGREEMENT (this “Agreement”) is entered into as of April 12, 2018 (the “Effective Date”), by and between SYNTHORX, INC.,
a Delaware corporation (“Synthorx”), with its principal place of business located at 11099 North Torrey Pines Road, Suite 290, La Jolla, CA 92037, USA, and CYTOVANCE BIOLOGICS,
INC., an organization organized under the laws of Delaware (“Provider”), having its principal place of business located at 800 Research Parkway, Suite 200, Oklahoma City, OK 73104. 

RECITALS 

WHEREAS, Synthorx is engaged in the research and development of pharmaceutical products; 

WHEREAS, Provider has personnel, expertise and facilities suitable for conducting pharmaceutical research
and/or development services on behalf of Synthorx; and 
 WHEREAS, Synthorx and Provider desire to
enter into this Agreement to govern the relationship between the parties and to define the conditions under which Provider will perform services on behalf of Synthorx. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and premises
contained in this Agreement, the receipt and sufficiency of which are hereby expressly acknowledged, the parties hereto agree as follows: 
  

	1.	 DEFINITIONS. 

1.1        “Batch” shall mean drug substance (the active
pharmaceutical ingredient of Synthorx Product in bulk form as described in the applicable Work Order) or drug product (the active pharmaceutical ingredient of Synthorx Product in filled form as described in the applicable Work Order) that is
intended to be of uniform character and quality, within specified limits, and is produced during the same cycle of manufacture as defined in the applicable batch records. 

1.2        “C.F.R.” shall mean the Code of Federal
Regulations, as amended. 
 1.3        “cGMP” shall mean (a)
“current Good Manufacturing Practices” or “cGMP” as promulgated under U.S. Food, Drug & Cosmetics Act (21 U.S.C. §301 et seq.) and the regulations thereunder including 21 Code of Regulations chapters 210 and
211, as amended from time to time. 
 1.4         “Confidential
Information” shall have the meaning provided in Section 7.2. 

1.5        “Conforming Batch” shall mean a Batch that was made
in accordance with agreed-upon Batch records, the Work Order, and, where applicable, cGMP. 

1.6        “Intellectual Property” shall have the meaning
provided in Section 5.1. 

 1.7        “Latent
Defect” shall mean a non-conformance in a Batch caused by Provider that: (i) is not discoverable upon commercially reasonable physical inspection and testing, (ii) causes the Batch to fail
to conform to the applicable Work Order or cGMP (if applicable), and (iii) is discovered within one (1) month of Synthorx’s acceptance of the Batch as a conforming Batch pursuant to Section 6.1(d) or (e). Any non-conformance in a Batch discovered more than one (1) month after Synthorx’s acceptance of such Batch is not a Latent Defect. 

1.8        “Materials” shall have the meaning provided in
Section 2.6. 
 1.9        “Project” shall have the
meaning provided in Section 2.2. 

1.10        “Protocol” shall mean a written protocol, approved
in writing by Synthorx, detailing the instructions for conducting a particular Project (or portion thereof). Each Protocol shall be attached to the applicable Work Order and incorporated therein. A Protocol may only be amended upon Synthorx’s
written approval, which such amendment shall be attached to the original Protocol and incorporated therein. 

1.11        “Provider Technology” shall have the meaning
provided in Section 5.2. 
 1.12        “Regulatory
Authority” shall mean any U.S. regulatory or governmental authority, such as the U.S. Food and Drug Administration, and the European Agency for the Evaluation of Medicinal Products, or any successor agencies thereto. 

1.13        “Results” shall have the meaning provided in
Section 2.5. 
 1.14        “Services” shall mean the
particular tasks to be performed by Provider in conducting a particular Project pursuant to this Agreement, as more fully set out in the applicable Work Order. 

1.15        “Synthorx Product” shall mean, if applicable, a
particular Synthorx drug candidate, pharmaceutical product, or other therapeutic product for which Provider shall conduct a Project, as identified with particularity in the applicable Work Order. 

1.16        “U.S.C.” shall mean the United States Code, as
amended. 
 1.17         “Work Order” shall have the meaning
provided in Section 2.2. 
 1.18        “Work Product”
shall mean any and all results (including Results) and products (interim and/or final) of the Services performed by Provider, whether tangible or intangible, including, without limitation, all data that is generated, and each and every invention,
discovery, design, drawing, protocol, process, technique, formula, trade secret, device, compound, substance, material, pharmaceutical, method, software program (including, without limitation, object code, source code, flow charts, algorithms and
related documentation), listing, routine, manual and specification, whether or not patentable or copyrightable, that are made, developed, perfected, designed, conceived or first reduced to practice by Provider, either solely or jointly with others,
in the course and as a result of performing the Services. 

  
 2. 

	2.	 SCOPE OF WORK. 

2.1      Scope of Agreement. As a master form of contract, this Agreement allows
the parties to contract for multiple Projects through the issuance of multiple Work Orders (as discussed in Section 2.2 below), without having to re-negotiate the basic terms and conditions contained
herein. 
 2.2      Work Orders. The specific research or development
activities to be performed, or other services to be provided, by Provider for each project under this Agreement (each, a “Project”) shall be separately specified on a
Project-by-Project basis in writing on terms and in a form acceptable to the parties (each such writing, a “Work
Order”). The Protocol(s) applicable to a particular Project shall be attached to, and are hereby incorporated by reference in, the corresponding Work Order. The Work Order for each Project will be attached hereto as a new
“Work Order No.         ” as part of Exhibit A. Each Work Order shall be signed by both parties and shall set forth, upon terms mutually agreeable to the
parties, the specific Services to be performed by Provider, the time line and schedule for the performance of such Services and the compensation to be paid by Synthorx to Provider for the provision of such Services, as well as any other relevant
terms and conditions. If a Project includes the development of specific Work Product, the specifications of such Work Product shall be set forth in the relevant Work Order. If a Project involves a clinical trial or any other study the results of
which are expected or intended to be submitted to any Regulatory Authority, the relevant Work Order shall specify: (a) any particular laws, rules, regulations, guidelines and standards (e.g., cGMP) of any Regulatory Authority or other
body that Provider is to comply with in performing such Project; and (b) any obligations to be transferred to Provider pursuant to 21 C.F.R. § 312.50 or other applicable laws, rules and regulations in connection with such Project. There
shall be no minimum or maximum number of Work Orders to be entered into under this Agreement. Each Work Order shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details set forth in the Work Order. To
the extent any terms or provisions of a Work Order conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control, except to the extent such Work Order specifically states the parties’ intent
that such Work Order control with respect to a particular matter. The parties shall attach a copy of each Work Order to this Agreement, and each such Work Order shall be incorporated herein by reference. Any changes to such Work Order shall be in
writing, executed by each party, attached to the original Work Order and incorporated therein and attached hereto as part of Exhibit A. 

2.3      Compliance with Work Orders and Law. Provider agrees to perform the
Services set forth in each Work Order in a competent and professional manner and in strict accordance with the terms and conditions contained in this Agreement, such Work Order and any applicable Protocol(s). Provider shall perform its obligations
hereunder in conformance with all applicable federal, state and local statutes, rules and regulations, including, if applicable, cGMP. If government regulatory requirements are changed, then Provider shall comply with the new requirements. If
compliance with new regulatory requirements necessitates a change in a Work Order, Provider will obtain Synthorx’s written consent to such change prior to implementation. Provider shall comply strictly with the applicable Protocol in performing
the Services for a Project. 
 2.4      Synthorx’s Approval of
Subcontractors. Provider shall not subcontract any of the Services under a Work Order without Synthorx’s prior written consent. Provider shall at all 

  
 3. 

 
times be responsible for the compliance of its permitted subcontractors with the terms and conditions of this Agreement and the applicable Work Order. However, Provider shall have no
responsibility for the acts or omission of any subcontractors that Synthorx requires Provider to use for subcontracted Services. 

2.5      Results. All data generated by Provider or its employees, agents,
consultants, Synthorx-approved subcontractors or other representatives in the course of conducting a Project, whether in written, graphic or electronic form or contained in any computer database or in any computer readable form (collectively, the
“Results”), will be owned solely by Synthorx. Provider shall record, or cause to be recorded, all Results in a timely, accurate and complete manner. All Results collected shall be delivered to
Synthorx by Provider in a timely manner throughout the performance of each Project, and, except as otherwise specified in the applicable Work Order, Provider shall deliver a final report of the Results of each Project to Synthorx no event later than
14 days after completion or termination of such Project or termination of this Agreement. Synthorx shall have the right to review, publish, disclose and use any Results as Synthorx, in its sole discretion, deems appropriate, including, without
limitation, in submission to any Regulatory Authority. Any copyrightable work created in connection with the performance of a Project and contained in or relating to the Results will be considered a work made for hire, whether published or
unpublished, and all rights therein will be the property of Synthorx as author and owner of copyright in such work. For purposes of clarification, this section shall apply to each Project individually. 

2.6      Materials. Synthorx agrees to provide at no cost to Provider the
applicable biological and/or chemical materials necessary for performance of a Project as specified in the applicable Work Order, which may include, without limitation, Synthorx Product (collectively,
“Materials”), in amounts sufficient for the conduct of the Project. All such Materials will remain the sole property of Synthorx, will be used only in furtherance of the Services in accordance with
this Agreement and Work Orders, will not be used or delivered to or for the benefit of any third party without the prior written consent of Synthorx, and will be used in compliance with all applicable laws, rules and regulations. Synthorx at all
times throughout the term of this Agreement shall retain all rights, title, and interest in and to the Materials used in the Services, or has obtained the necessary permission to transfer the Materials to Provider for use in the Services. Unless
otherwise stated in a Work Order, the Materials do not have hazardous properties and no specific safe handling instructions are applicable. If requested by Provider, Synthorx will supply Provider with a material safety data sheet for any Materials.
Provider is under no obligation to produce products which are classified as antibiotics, cytotoxic, or highly active drugs, or are complexed with radioisotopes, all of which generally require segregated and specialized facilities and equipment.
Other than the foregoing statements regarding the Materials, THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF
FITNESS FOR ANY PARTICULAR PURPOSE. 
  

	3.	 PAYMENT AND BUDGET. 

3.1      Estimated Budget; Accounting. Except to the extent a Work Order provides
for Provider to perform Services on a fixed-fee basis, each Work Order shall contain an estimated 

  
 4. 

 
budget for the performance of the Work Order, as well as additional terms and conditions relating to such estimated budget, and Provider will provide to Synthorx, at intervals stated in each Work
Order, an accounting of costs incurred and accrued to date for Services under the applicable Project. 

3.2      Invoices; Payment. Unless otherwise agreed by the parties in writing,
Provider shall provide to Synthorx for each Work Order one or more separate invoices (to be delivered at intervals specified in such Work Order), such invoice summarizing the Services performed during that period of time under that Work Order and
the fees and costs therefor. Synthorx shall pay each invoice within [...***...] of receipt thereof, in accordance with the applicable schedule of payments specified in such Work Order. Late payments are subject to an interest charge of
[...***...]% per month on the outstanding balance. Provider’s failure to bill for interest due shall not be a waiver of Provider’s right to charge interest. Synthorx shall not be obligated to pay any amounts in excess of the fixed
fee, budget or other payments (as applicable) specified in a Work Order that have not been approved in writing by Synthorx in advance. 

3.3      Taxes. Provider will be liable for [...***...] imposed with respect
to Provider’s performance of Services, except for applicable sales and use taxes that by law Provider must add to the cost of Services and which are separately stated on Provider’s invoice. Synthorx shall pay all [...***...] assessed
upon or levied against the sale of Synthorx Product to Synthorx pursuant to this Agreement or the sale or distribution of Synthorx Product by Synthorx (or at Synthorx’s sole expense, defend against the imposition of such taxes and expenses).
Provider shall notify Synthorx of any such taxes that any governmental authority is seeking to collect from Provider, and Synthorx may assume the defense thereof in Provider’s name, if necessary, and Provider agrees to fully cooperate in such
defense to the extent of the capacity of Provider, [...***...]. 

3.4      Records Audit. Except to the extent a Work Order provides for
Provider to perform Services on a fixed-fee basis, Synthorx and/or an independent accounting firm appointed by Synthorx, [...***...], shall have the right to audit Provider’s financial records
relating to a Project during the time such Project is ongoing under this Agreement once per calendar year ; provided, that any such audit(s) shall be conducted upon reasonable advance notice to Provider, at a mutually agreed upon time and
duration, and during Provider’s normal business hours. 
  

	4.	 REGULATORY. 

4.1      Regulatory Inspections. If any Regulatory Authority conducts, or gives
notice to Provider of its intent to conduct, an inspection at Provider’s facilities where any Project or Services are currently being performed or to take any other regulatory action with respect to any Project or Services, Provider will use
[...***...] to notify Synthorx in writing prior to complying with such a demand or request. If the Regulatory Authority inspection or other regulatory action is specific only to Synthorx Project, subject to the consent of the Regulatory
Authority, a Synthorx representative may be present at any such inspections and shall have the opportunity to provide, review, and comment on any required responses pertaining to the Synthorx Product. 

  
 ***Confidential
Treatment Requested 
 5. 

 4.2      Site Visits by
Synthorx. Once per calendar year, up to two representatives of Synthorx may visit and/or meet with Provider or Synthorx-approved subcontractors at for up to two days during normal business hours to observe the progress of all Projects, perform
routine audits and/or functional evaluations, and review relevant records. Provider shall assist Synthorx in scheduling such visits at mutually agreeable times at no extra charge. Provider agrees to identify a representative of their independent
Quality Assurance unit, as applicable, to act as a liaison to a representative of Synthorx Quality Unit. The audits may take place over a longer duration if agreed to by Synthorx and Provider. 

4.3      Record-Keeping. Provider shall maintain records of documents,
information, data and materials used or generated in performance of the Services (including, without limitation, Work Product and Intellectual Property) in a professional manner so as to permit Synthorx to review such records in accordance with this
Section 4.3 without disclosing to Synthorx any third party confidential or proprietary information. Designated representatives of Synthorx shall, upon at least [...***...] advance notice to Provider, have access to and shall be permitted
to review all such records during the term of this Agreement and during the applicable retention period specified in Section 4.4. Upon Synthorx’s request, Provider will provide to Synthorx an inventory of records and record types
pertaining to any Project or Services, and upon request, a copy of any or all such records. 

4.4    Retention of Records. Subject to the provisions of Article 7, Provider may
retain in its possession copies of any and all data, documents or information related to the performance of this Agreement solely as required for regulatory, legal or insurance purposes. Except as expressly set forth in any Work Order(s), Provider
shall maintain: all such records that relate in any way to a Synthorx Product, until the latest of: (i) [...***...] following the completion date of the applicable Project for the Synthorx Product; and (ii) [...***...] required
by applicable laws, rules and regulations. At the end of the stated retention periods, Provider will contact Synthorx, and Synthorx will choose to have the retained records transferred to their control or authorize Provider to destroy records or
transfer them to an offsite storage facility. Notwithstanding anything to the contrary in this paragraph, Provider may indefinitely keep all validation and technical transfer documents in connection with the Services performed for Synthorx. 

4.5      Retention of Samples. Provider will retain samples of raw
materials, packaging materials, labeling, intermediates (if applicable), and final Synthorx Product for [...***...] after the release date under the conditions stated in the respective material specifications. At the end of the
retention period, Provider will contact Synthorx and request written permission to transfer the retained samples to Synthorx or have them destroyed. If no response is received after [...***...] from the end of the retention period, Provider
will have the right to destroy the retained samples. 
  

	5.	 OWNERSHIP OF INTELLECTUAL PROPERTY.

 5.1      Work Product. Provider understands and
agrees that the underlying rights to the intellectual property and Materials that are the subject of each Work Order, including, without limitation, all intellectual property rights in Synthorx Products, are owned solely by Synthorx. Neither
Provider nor any Synthorx-approved subcontractor shall acquire any rights of any kind 

  
 ***Confidential
Treatment Requested 
 6. 

 
whatsoever with respect to Synthorx Products as a result of conducting a particular Project. Except as expressly set forth in Section 5.2, all right, title and interest in and to Work
Product generated in the performance of work conducted under this Agreement by Provider’s employees, agents, consultants, subcontractors or other representatives, either solely or jointly with employees, agents, consultants or other
representatives of Synthorx, including all patent and other intellectual property rights therein (collectively, the “Intellectual Property”), will be owned solely by Synthorx. Provider hereby
assigns to Synthorx any and all rights that Provider may have in and to the Work Product and Intellectual Property. Provider represents and warrants to Synthorx that each employee, agent, consultant and subcontractor of Provider is obligated to
assign all of his/her/its right, title and interest in and to Intellectual Property to Provider. Provider and all employees, agents, consultants and subcontractors of Provider shall sign and deliver to Synthorx all writings and do all such things as
may be necessary or appropriate to vest in Synthorx all right, title and interest in and to such Work Product and Intellectual Property. Provider will promptly disclose to Synthorx any such Work Product arising under this Agreement. Synthorx may, in
its sole discretion, file and prosecute in its own name and [...***...], patent applications on any patentable inventions within the Work Product. Upon the request of Synthorx, [...***...], Provider will assist Synthorx in the
preparation, filing and prosecution of such patent applications and will execute and deliver any and all instruments necessary to effectuate the ownership of such patent applications and to enable Synthorx to file and prosecute such patent
applications in any country. 
 5.2      Provider Technology. Work
Product shall not include any Provider proprietary technology existing prior to the Effective Date or that is developed by Provider independent of any activities conducted pursuant to this Agreement (“Provider
Technology”), and, as between the parties, all such Provider Technology shall be owned solely by Provider. In order to provide Synthorx with
freedom-to-operate with respect to Synthorx Products, Work Product and Intellectual Property, Provider hereby grants to Synthorx a limited worldwide, royalty-free, non-exclusive license, including the right to sublicense through multiple tiers of sublicense, to use Provider Technology solely if and to the
extent necessary for the development, manufacture, use, sale, offer for sale and import of Synthorx Products, Work Product and Intellectual Property. 

5.3      No Implied License. Neither Synthorx nor Provider transfers to the other
by operation of this Agreement any patent right, copyright right, trademark right or other proprietary right of any party, except as expressly set forth in this Agreement. 
  

	6.	 PRODUCT ACCEPTANCE AND TESTING;
DELIVERY; RECALLS. 

6.1      Acceptance and Testing. 

(a)      Testing by Provider. Each Batch will be sampled and tested by Provider
in accordance to the approved Batch record, and Provider will review the documentation to assess if the Batch is a Conforming Batch. 

(b)      Provision of Records. If, based upon such tests and documentation
review, Provider determines that a Batch is a Conforming Batch, then the Batch documentation for each Batch of drug substance or drug product will be delivered to Synthorx by an agreed upon courier. 

  
 ***Confidential
Treatment Requested 
 7. 

 (c)      Review of Batch
Documentation. Synthorx will notify Provider in writing of its acceptance or rejection of such Conforming Batch within [...***...] of receipt of the complete Batch documentation relating to such Batch. During this review period, the
parties agree to respond promptly, but in any event within [...***...], to any reasonable inquiry or request for a correction or change by the other party with respect to such Batch documentation. 

(d)      Failure to Accept or Reject. If Synthorx does not notify Provider within
the applicable time period that the Batch does not conform to the Work Order or cGMP (if applicable), then Synthorx will have accepted the Batch as a Conforming Batch and waived its right to revoke acceptance, and the drug substance or drug product
must be deemed a conforming Synthorx Product. 
 (e)      Dispute Regarding Batch.
In case of any disagreement between the parties as to whether a Batch conforms to the relevant Work Order or cGMP (if applicable) Synthorx shall notify Provider in writing, including a detailed explanation of the
non-conformity. The quality assurance representatives of the Parties will attempt in good faith to resolve any such disagreement and Synthorx and Provider will follow their respective standard operating
procedures to determine the conformity of the Batch to the Work Order and cGMP (if applicable). If the foregoing discussions do not resolve the disagreement in a reasonable time (which must not exceed [...***...]), a representative sample of
such Batch and/or relevant documentation will be submitted to an independent testing laboratory (in the case of an alleged failure to conform to the relevant Work Order) and/or independent cGMP consultant (in the case of an alleged failure to comply
with cGMP), mutually agreed upon by the parties, for tests and final determination of whether the Batch conforms with such Work Order and/or cGMP (if applicable). The laboratory and retesting of the Batch must comply with cGMP (if applicable). The
laboratory or consultant, as applicable, must be of recognized standing in the industry. Neither party may unreasonably withhold consent to the appointment of such laboratory and consultant. Such laboratory will use the test methods contained in the
relevant Work Order. The determination of conformance by such laboratory and/or cGMP consultant, as applicable, with respect to all or part of such Batch will be final and binding on the parties absent manifest error. The fees and expenses of the
laboratory and/or consultant, as applicable, incurred in making such determination shall be paid by the party against whom the determination is made. 

(f)      Latent Defect. In the event Synthorx discovers a Latent Defect in a Batch
after Synthorx previously accepted such Batch as a Conforming Batch pursuant to paragraphs (d) or (e) of this Section, Synthorx will have one month from the date of acceptance of that Batch to reject such Batch because of the Latent Defect.
Notice of rejection of a Batch because of a Latent Defect must be in writing and sent to Provider by certified mail or nationally recognized express courier service within two weeks of the discovery of the Latent Defect, and such notice must include
a detailed explanation as to why the alleged Latent Defect does not adhere to the applicable Work Order or cGMP (if applicable). Any disagreement as to whether the Latent Defect causes the subject Batch to fail to conform to the applicable Work
Order or cGMP (if applicable) will be resolved in accordance with the procedures set forth in paragraph (e) of this Section. 

(g)      Remedy. If Provider admits that a Batch fails to conform to the
applicable Work Order or cGMP (if applicable), or the laboratory or consultant (as described in paragraph (e) of this Section), after taking into consideration Provider’s acts and omissions, Synthorx’s acts and

  
 ***Confidential
Treatment Requested 
 8. 

 
omissions, and any deficiency in the Materials, data, methods, processes, intellectual property, or other information supplied by Synthorx to Provider, determines that a Batch fails to conform to
the applicable Work Order or cGMP (if applicable) primarily as a result of Provider’s acts or omissions, then, as Synthorx’s sole remedy, [...***...], and subject to Synthorx, [...***...], supplying the replacement Materials,
Provider will, within the time period required to prepare such Batch as described in the applicable timeline from receipt of replacement Materials, reprocess such Batch, or formulate from the beginning if unable to reprocess, so that it conforms
with the relevant Work Order or with cGMP (if applicable). Manufacturing deviations and investigations that occur during production and do not cause the Batch to be non-compliant with cGMP will not be deemed
to result in a non-conforming Batch. 

6.2      Delivery of Product. Unless otherwise agreed in writing by the parties,
all Synthorax Product, samples, components, or other materials shipped by Provider to Synthorx are delivered F.O.B. Provider’s facilities. Provider shall package for shipment such Synthorax Product, samples, components, or other materials
[...***...] and in accordance with Synthorx’s full written and reasonable instructions. Synthorx shall procure, [...***...], insurance covering damage or loss of Synthorx Product during shipping. All shipping instructions of
Synthorx shall be accompanied by the name and address of the recipient and the shipping date. 

6.3      Exports and Recalls. 

(a)      Exporter of Record. Synthorx remains the owner of the Synthorx Product
and shall be the exporter of record for any Synthorx Product shipped out of the United States. Synthorx warrants that all shipments of Synthorx Product exported from the United States will be made in compliance with all applicable United
States export laws and regulations and all applicable import laws and regulations into the country of deportation. Synthorx shall be responsible for obtaining [...***...] any licenses, clearances, or other governmental authorization(s)
necessary for the exportation from the United States. Synthorx shall select [...***...] the freight forwarder, who will solely be Synthorx’s agent. Synthorx and its freight forwarder shall be solely responsible for preparing and filing
the shipper’s export declaration and any other documentation required for the export. In connection with each delivery of Synthorx Product, Provider will deliver to Synthorx all certificates of analysis, certificates of conformity, and such
other documentation as is required to meet all requirements under applicable law with respect to such Synthorx Product. 

(b)      Synthorx Product Recalls. In the event Synthorx shall be required to
recall any Synthorx Product because such Synthorx Product may violate local, state, or federal laws or regulations, or the laws or regulations of any applicable foreign government or agency, or in the event that Synthorx elects to institute a
voluntary recall, withdrawal, field alert or similar action (collectively a “Recall”), Synthorx shall be responsible for coordinating such Recall. Synthorx promptly shall notify Cytovance if any Synthorx Product is the subject of a Recall
and provide Cytovance with a copy of all documents relating to such Recall. Synthorx shall be responsible for all of the costs and expenses of such Recall. 

  
 ***Confidential
Treatment Requested 
 9. 

	7.	 CONFIDENTIALITY. 

7.1      Confidentiality Obligation. [...***...], each party will
maintain all Confidential Information (as defined below) as confidential and will not disclose any Confidential Information or use any Confidential Information for any purpose, except (a) as expressly authorized by this Agreement, (b) as
permitted by Section 7.3, or (c) to its employees, agents, consultants, Synthorx-approved subcontractors and other representatives who require access to such information to accomplish the purposes of this Agreement so long as such persons
are under obligations regarding the confidentiality of the Confidential Information and the ownership of Work Product that are consistent with and no less protective to Synthorx than the terms of this Agreement. Each party may use the Confidential
Information of the other party only to the extent required to accomplish the purposes of this Agreement. Each party will use at least the same standard of care as it uses to protect its own confidential information to ensure that its employees,
agents, consultants, Synthorx-approved subcontractors and other representatives do not disclose or make any unauthorized use of the Confidential Information. Each party will promptly notify the other upon discovery of any unauthorized use or
disclosure of the other party’s Confidential Information. 

7.2      Definition. For purpose of this Agreement,
“Confidential Information” means any confidential data or information disclosed by a party in writing, visually, orally or in electronic medium to the receiving party under this Agreement, including, without limitation, Work
Product, Results, Intellectual Property, and all data, inventions, and information developed in or as a result of the performance of this Agreement, whether in oral, written, graphic or electronic form. Without limiting the generality of the
foregoing, all intellectual property of either party shall be deemed the “Confidential Information” of such party. Notwithstanding the foregoing, Confidential Information will not include any information which a party can demonstrate by
competent written evidence: (a) is now, or hereafter becomes, through no act or failure to act on the part of that party or any of its employees, agents, consultants or subcontractors, generally known or available; (b) is known by that
party at the time of receiving such information (or, as applicable, generating such information pursuant to this Agreement), as evidenced by its pre-existing written records; or (c) is hereafter furnished
to that party by a third party, as a matter of right and without restriction on disclosure. 

7.3      Authorized Disclosure. Notwithstanding the provisions of
Section 7.1, either party may disclose the other party’s Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is required by a valid order of a court or other governmental body
having jurisdiction or is otherwise required by law or regulation, provided that the party gives reasonable prior written notice to the other party of such required disclosure and, at the other party’s request and expense, cooperates
with the other party’s efforts to contest such requirement, to obtain a protective order preventing or limiting the disclosure, requiring that the Confidential Information so disclosed be used only for the purposes for which the order was
issued or the law or regulation requires, and/or to obtain other confidential treatment of the Confidential Information so disclosed. 

7.4      Third Party Confidential Information. Neither party shall disclose to the
other party any confidential or proprietary information that belongs to any third party. 

  
 ***Confidential
Treatment Requested 
 10. 

	8.	 REPRESENTATIONS AND WARRANTIES. 

8.1      Mutual Representations and Warranties. Each party represents and warrants
that (a) it has full power and authority to enter into this Agreement, (b) this Agreement has been duly authorized, and (c) this Agreement is binding upon it. 

8.2      Provider Representations and Warranties. Provider represents and warrants
that: (a) Provider is not constrained by any existing agreement in providing complete disclosures to Synthorx concerning obligations to be performed under this Agreement; (b) Provider will render the Services in accordance with industry
standards of professional conduct and in compliance with the terms of this Agreement, the terms of the Work Orders, and all applicable federal, state and local statutes, rules and regulations, including, if applicable, cGMP; and (c) the
personnel assigned to perform Services rendered under this Agreement shall be qualified and professionally capable of performing the Services. Provider further represents and warrants that, as of the Effective Date, there are no pending warnings
(i.e., warnings to which Provider has not responded) issued to Provider by any Regulatory Authority relating to services it has provided to third parties relating to any a clinical trial. 

8.3      No Debarment. Provider hereby represents and warrants that it has not
been debarred under the provisions of 21 U.S.C. §335a (“Debarred”). In the event that during the term of this Agreement Provider becomes Debarred, or receives notice of action or threat of action to have Provider
Debarred, Provider agrees to notify Synthorx immediately. In either such event, Synthorx will have the right to terminate this Agreement upon written notice to Provider. Provider further represents and warrants that it has not used, and covenants
that it will not use, in any capacity, the services of any individual, corporation, partnership, institution or association which has been Debarred. In the event Provider becomes aware that any individual, corporation, partnership, institution or
association providing services to Provider which directly or indirectly relate to Provider’s activities under this Agreement has been Debarred, or has received notice of action or threat of action to have such entity Debarred, Provider will
notify Synthorx immediately, in which event Synthorx will have the right to terminate this Agreement upon written notice to Provider. 

8.4      Synthorx Representations and Warranties. Synthorx hereby
represents and warrants that Synthorx shall: (i) provide complete and accurate scientific data necessary to Provider’s performance of Services; (ii) provide Provider with all information necessary to effect the reliable transfer of
methods to Provider for performance of the Services; (iii) provide Provider with sufficient Materials necessary for the performance of Services; (iv) if applicable, review and approve in-process and
finished Synthorx Product test results, regardless of which party is responsible for finished Synthorx Product release; (v) be responsible for the preparation of all Synthorx Product-related submissions to Regulatory Authorities; and
(vi) perform any and all other obligations set forth in the relevant Work Order and Quality Technical Agreement 

8.5      Materials. Synthorx hereby represents and warrants that Provider’s
use of the Materials, data, intellectual property, and other information provided to Provider by Synthorx, and the Synthorx Product produced in accordance with this Agreement, will not violate or infringe on any patents, trademarks, service marks,
copyrights, or any other intellectual property or confidential information of any third party. 

  
 11. 

 8.6      Disclaimer of
Warranties. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE. 
 8.7      Limitation of Liability. Synthorx’s sole and
exclusive remedy for non-conforming Synthorx Product or deliverables is limited to those remedies set forth in Section 6.1 EXCEPT FOR GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, IN NO EVENT SHALL EITHER PARTY BE
LIABLE TO THE OTHER FOR ANY LOST PROFITS, LOST SAVINGS, OR ANY OTHER INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, ARISING OUT OF OR IN CONNECTION WITH THIS
AGREEMENT; provided, however, that this Section 8.7 shall not be construed to limit either party’s indemnification obligations under Article 10. 
  

	9.	 TERM AND TERMINATION. 

9.1      Term. The term of this Agreement shall commence on the Effective Date
and, unless earlier terminated in accordance with this Article 9, shall expire on the fifth anniversary of the Effective Date, except that if Services under any Work Order are in progress on the fifth anniversary of the Effective
Date, this Agreement shall expire upon completion of such Services. 

9.2      Termination for Material Breach. A party may terminate this Agreement or
any Work Order for material breach of this Agreement by the other party upon 30 days’ written notice specifying the nature of the breach, if such breach has not been cured within such 30-day period.
If such notice of breach is for breach of a Work Order, such notice shall note the specific Work Order under which such breach is claimed. 

9.3      Termination At Will. 

(a)      By Synthorx. Synthorx may terminate this Agreement or any Work
Order at any time upon 60 days’ prior written notice to Provider. Notwithstanding the foregoing, if Services under any one or more Work Orders are in progress on the date Synthorx gives such notice of termination, then, at Synthorx’s
option, termination under this Section 9.3(a) shall not be effective with respect to any such Work Order(s) specified by Synthorx until the later of (i) 60 days after the date on which Provider receives such notice of termination, or
(ii) the date on which the Services to be provided under the Work Order(s) have been completed. 

(b)      By Provider. Provided that all Services to be performed pursuant to all
Work Orders under this Agreement have been completed (or terminated in accordance with this Article 9), Provider may terminate this Agreement on 60 days’ written notice to Synthorx. 

9.4      Termination for Bankruptcy. This Agreement may be terminated at
any time during by either party upon the other party’s filing or institution of bankruptcy, reorganization, liquidation, or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by
the other party. 

  
 12. 

 9.5      Consequences of
Termination. In the event of early termination of any individual Work Order for a Project, or in the event of termination of this Agreement and all Work Orders for all Projects, Synthorx shall pay to Provider all sums owing to Provider for
Services completed up to the effective termination date of such Work Order(s) and all non-cancelable obligations reasonably incurred before the effective date of termination pursuant to such Work Order(s)
within 60 days after the effective date of termination. Subject to the preceding sentence, Provider shall refund to Synthorx any prepaid amounts not earned by Provider prior to the date of such termination. Additionally, in the event of early
termination of the manufacturing of any non-cGMP Batch, Synthorx shall pay to Provider a cancellation fee based on a percentage of the fees owed to Provider for completion of such Batch (a “Cancellation
Fee”) as follows: 
  

			
	 Days Prior Notice to Provider
	 	 Cancellation Fee as a Percent of Fees for

Canceled non-cGMP Batch

	 > 121
	 	0%
	 91 to 120
	 	15%
	 61 to 90
	 	50%
	 30 to 60
	 	75%
	 < 30
	 	100%

 In the event of early termination or rescheduling of the manufacturing of any cGMP Batch, Synthorx shall pay
to Provider a cancellation fee based on a percentage of the fees owed to Provider for completion of such cGMP Batch (a “Cancellation Fee”) as follows: 
  

			
	 Days Prior Notice to Provider
	 	 Cancellation/Rescheduling Fee as a Percent of

Fees for canceled cGMP Batch

	 > 271
	 	0%
	 181 to 270
	 	25%
	 91 to 180
	 	50%
	 61 to 90
	 	75%
	 30 to 60
	 	90%
	 < 30
	 	100%

 Notwithstanding the above Cancellation Fees, Provider shall use commercially reasonable efforts to utilize
resources that would have been used for Synthorx had the termination/reschedule not occurred for a third-party customer who has not reserved capacity at the time of termination/reschedule. Provider shall reduce the payment due under this
Section 9.5 by a sum equal to the fee received by the third party customer (after accounting for out-of-pocket costs incurred by Provider to accomplish such
mitigation) for the costs of Provider’s labor and equipment that Provider would have expended on manufacturing Synthorx’s non-cGMP or GMP Batch, as the case may be. 

9.6      Survival Upon Termination. Expiration or termination of
this Agreement will not relieve the parties of any obligation accruing prior to such expiration or termination. Sections 2.5, 2.6, 4.3, 4.3, 8.4, 8.7, 9.4 and 9.6 and Articles 4.5, 6, 10 and 11 shall survive expiration or termination of
this Agreement. 

  
 13. 

	10.	 INDEMNIFICATION. 

10.1      Synthorx Indemnification. Synthorx hereby agrees to save, defend,
indemnify and hold harmless Provider and its officers, directors, employees, consultants and agents (“Provider Indemnitees”) from and against any and all losses, damages, liabilities, expenses and
costs, including reasonable legal expense and attorneys’ fees (“Losses”), to which any such Provider Indemnitee may become subject as a result of any claim, demand, action or other proceeding
by any third party to the extent such Losses arise out of: (a) its breach, violation, non-compliance, or non-performance of any of the terms of this Agreement;
(b) the gross negligence or willful misconduct of any Synthorx Indemnitee; (c) the development, manufacture, use, handling, storage, marketing, sale or other disposition of any Synthorx Product by or on behalf of Synthorx; or (d) any
assertion that a Provider’s Indemnitee’s use of any Materials, data, methods, processes, intellectual property, or other information supplied by Synthorx or on behalf of Synthorx infringes the patents, trademarks, service marks,
copyrights, or any other intellectual property rights or confidential information rights of a third party; except, in each case, to the extent such Losses result from the material breach by Provider of any representation, warranty, covenant or
agreement made by it under this Agreement or the negligence or willful misconduct of any Provider Indemnitee. 

10.2      Provider Indemnification. Provider hereby agrees to save, defend,
indemnify and hold harmless Synthorx and its officers, directors, employees, consultants, contractors and agents (“Synthorx Indemnitees”) from and against any and all Losses to which any such
Synthorx Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any third party to the extent such Losses arise out of its breach, violation, non-compliance, or non-performance of any of the terms of this Agreement or the gross negligence or willful misconduct of any Provider Indemnitee; except, in each case, to the extent such Losses result from the material breach by
Synthorx of any representation, warranty, covenant or agreement made by it under this Agreement or the gross negligence or willful misconduct of any Synthorx Indemnitee. 

10.3      General Conditions of Indemnification. A party’s agreement to
indemnify, defend and hold the other party (the “Indemnified Party”) and its related entities harmless is conditioned upon the Indemnified Party: (a) providing written notice to the first party (the
“Indemnifying Party”) of any claim, demand or action arising out of the indemnified activities within [...***...] after the Indemnified Party has knowledge of such claim, demand or action (late notice will not absolve
an Indemnifying Party of its indemnification obligations to the Indemnified Party, [...***...]); (b) permitting the Indemnifying Party to assume full responsibility and authority to investigate, prepare for and defend against any such
claim or demand; (c) assisting the Indemnifying Party, [...***...], in the investigation of, preparation for and defense of any such claim or demand; and (d) not compromising or settling such claim or demand without the Indemnifying
Party’s written consent. 
 10.4      Insurance. 

(a)      Provider Insurance. Provider, [...***...], shall secure and
maintain in full force and effect throughout the term of this Agreement insurance coverage for general, professional and contractual liability (including errors and omissions coverage) [...***...]

  
 ***Confidential
Treatment Requested 
 14. 

 
[...***...] in light of Provider’s obligations hereunder (but no less than $[...***...] of coverage) with a reputable A-rated insurance
company. In addition, Provider shall secure and maintain in full force and effect throughout the term of this Agreement workers’ compensation insurance in the amount required by the laws of any state in which any of Provider’s employees
performing Services hereunder are located. Provider shall provide a certificate of insurance evidencing the required coverage under this Section 10.4 to Synthorx upon request 

(b)      Synthorx Insurance. Synthorx shall procure and maintain,
[...***...] of all Synthorx Product produced under this Agreement, commercial general liability insurance, including without limitation, clinical trial product liability and contractual liability coverage (the “Synthorx Insurance”).
The Synthorx Insurance shall cover amounts not less than [...***...] ($[...***...]) combined single limit and shall be with an insurance carrier reasonably acceptable to Provider. Provider shall be named as an additional insured on the
Synthorx Insurance and Synthorx shall deliver upon request a certificate of the Synthorx Insurance and endorsement of additional insured to Provider evidencing such coverage. If Synthorx fails to furnish such certificates or endorsements, or if at
any time during the Term Provider is notified of the cancellation or lapse of the Synthorx Insurance, and Synthorx fails to rectify the same within thirty (30) days after notice from Provider, Provider, at its option, may terminate this
Agreement. Any deductible and/or self-insurance retention shall be the sole responsibility of Synthorx. 
  

	11.	 GENERAL PROVISIONS. 

11.1      Independent Contractor Relationship. Provider’s relationship with
Synthorx will be that of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Provider is not an agent of Synthorx and is not authorized to make any
representation, contract, or commitment on behalf of Synthorx. Provider will be solely responsible for all tax returns [...***...] required to be filed with or made to any federal, state or local tax authority with respect to Provider’s
performance of services and receipt of fees under this Agreement. 
 11.2      Use
of Names. Neither party shall use the other party’s name or the names of the other party’s employees in any advertising, sales, promotional material or in any publication without prior written permission of the other party. 

11.3      Force Majeure. In the event of a delay caused by inclement weather,
fire, flood, act of war, act of terrorism, act of God, act of governmental officials or agencies, or any like cause beyond the control of the parties, the party or parties so affected shall be excused from performance hereunder for the period of
time attributable to such delay, which may extend beyond the time lost due to one or more of the causes mentioned above. In the event of any such delay, the parties may, in their sole discretion, revise this Agreement by changing the schedule of
payments in a given Work Order, the performance period, and other provisions, as appropriate, by mutual written agreement. 

  
 ***Confidential
Treatment Requested 
 15. 

 11.4      Governing Law. This
Agreement shall be governed by the laws of the State of Delaware, without regard to its conflicts of laws principles. 

11.5      Injunctive Relief. Each party hereby acknowledges and agrees that in the
event of that party’s breach of any provision of this Agreement relating to Materials, Confidential Information and/or Intellectual Property (including, without limitation, Section 2.6, Article 4.5 and Article 7), the other party
would suffer an irreparable injury such that no remedy at law would adequately protect or appropriately compensate the other party for such injury. Accordingly, the offending party agrees that the other party shall have the right to enforce this
Agreement and any of such provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the other party may have for a breach of this Agreement. 

11.6      Entire Agreement; Amendment. This Agreement, together with all Exhibits
attached hereto (each of which is incorporated herein by reference), constitutes the final, complete and exclusive agreement of the parties with respect to the subject matter hereof and supersedes all prior understandings and agreements relating to
its subject matter. This Agreement may not be changed, modified, amended or supplemented except by a written instrument signed by an authorized representatives of each of Synthorx and Provider. 

11.7      Non-Waiver. No failure or delay
of one of the parties to insist upon strict performance of any of its rights or powers under this Agreement shall operate as a waiver thereof, nor shall any other single or partial exercise of such right or power preclude any other further exercise
of any rights or remedies provided by law. Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by such party. 

11.8      No Third Party Beneficiaries. This Agreement is neither expressly
nor impliedly made for the benefit of any party other than those executing it. 

11.9      Severability. If any provision of this Agreement is found by a court of
competent jurisdiction to be unenforceable, then such provision will be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such provision, it will be severed from the remainder
of this Agreement. The remainder of this Agreement will remain in full force and effect, unless the severed provision is essential and material to the rights or benefits received by either party. In such event, the parties will negotiate, in good
faith, and substitute a valid and enforceable provision or agreement that most nearly implements the parties’ intent in entering into this Agreement. 

11.10      Successors and Assigns. Neither this Agreement nor any rights or
obligations hereunder may be assigned or otherwise transferred by either party without the prior written consent of the other party; provided, however, that Synthorx may assign this Agreement and its rights and obligations hereunder without
Provider’s consent to an affiliate of Synthorx or in connection with the transfer or sale of all or substantially all of Synthorx’s business to which this Agreement relates to an affiliate or third party, whether by merger, sale of stock,
sale of assets or otherwise. Notwithstanding the foregoing sentence, either party may, without the consent of the other party, assign this Agreement to its successor in interest in connection with the sale of all or

  
 16. 

 
substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. No assignment shall relieve either party of the
performance of any accrued obligation that such party may then have under this Agreement. The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the respective successors and permitted
assigns of the parties, and the name of a party appearing herein will be deemed to include the name of such party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. Any assignment not in
accordance with this Agreement shall be void. 
 11.11      Non-solicitation of Employees. From the Effective Date, and until [...***...], neither party shall, either directly or indirectly, whether through a third party or otherwise, solicit, recruit, encourage,
or induce any employee of or consultant or contractor to the other party to terminate his, her, or its relationship with such other party in order to accept or enter into any employment or independent contractor or other business relationship with
an employer, entity, or person other than such other party. Notwithstanding the foregoing, neither party shall be restricted from hiring any employee or contractor of the other party who, without solicitation by the other party, applies for an
advertised position and is subsequently hired by the other party. 

11.12      Notices. Any notice to be given under this Agreement must be in writing
and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, by overnight courier or by facsimile, to the party to be notified at its address(es) given below, or at any address such party has previously
designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if mailed, three days after the date of postmark; (c) if delivered
by express courier, the next business day the courier regularly makes deliveries to the addressee’s location; or (d) if delivered by facsimile, upon confirmation of transmission. 

 

					
		 	 If to Synthorx:
	  	 Synthorx, Inc.

11099 North Torrey Pines Road, Suite 290

La Jolla, CA 92037
 USA

Attn.:
                                    

Fax:

			
		 	 If to Provider:
	  	 Cytovance Biologics, Inc.

800 Research Parkway, Suite 200

Oklahoma City, OK 73104
 Attn.:
Chief Executive Officer

 11.13      Interpretation. The headings of clauses
contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its
interpretation or construction. All references in this Agreement to the singular shall include the 

  
 ***Confidential
Treatment Requested 
 17. 

 
plural where applicable. Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such Section and references in this Agreement to
any subsection shall include all paragraphs in such subsection. All references to days in this Agreement shall mean calendar days, unless otherwise specified. Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against
either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language, and the English language shall control its interpretation. In addition, all
notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement, shall be in the English language. 

11.14      Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all
purposes. 
 [Remainder of page intentionally left blank] 

  
 18. 

 IN WITNESS WHEREOF, the
parties have by duly authorized persons executed this Agreement as of the Effective Date. 
  

					
	 SYNTHORX, INC.
	  		  	 CYTOVANCE BIOLOGICS, INC.

			
	 By:   /s/ Laura Shawver,
Ph.D.                                
	  		  	 By:   /s/ Jesse
McCool                                        

			
	 Name: Laura Shawver,
Ph.D.                                  
	  		  	 Name: Jesse
McCool                                        
  

			
	 Title: President &
CEO                                         
   
	  		  	 Title:  SVP of
R&D                                        
    

  
 [SIGNATURE
PAGE TO MASTER SERVICES AGREEMENT] 

 Exhibit A 

Parties to use Provider’s Proporsal, attached hereto, as Work Order Format 

  
 A-3 

 

 
  
  

Revision 2 – Scope of Work for Contract Manufacturing Services: 

[...***...] Process Transfer for cGMP Production 

Prepared for: 
  

 
  
  

Client/Project Code: 
  

	
	  

123-18-000

 

 For Cytovance Finance Department Use 
  

 

					
			
		 	  

Responsive. Reliable. Resourceful.

 

Cytovance® Biologics
Inc.
 800 Research Parkway, Suite 200,

Oklahoma City, OK 73104

Phone: 405.319.8310

 
	  	 www.cytovance.com        

 

  
  

  
 ***Confidential Treatment
Requested 

 P a g e | 2 of 18 

 
  

	
	  A. Contact Information

  

			
	Synthorx, Inc.	 	Cytovance Biologics, Inc.
	 [...***...]

11099 N. Torrey Pines Road, Suite 290
 La Jolla,
CA 92037
 [...***...]

[...***...]
	 	 [...***...]

800 Research Parkway, Suite 200
 Oklahoma City,
OK 73104
 858.220.1597

kafansev@cytovance.com

  

	
	  B. Executive Summary

 Synthorx, Inc. (“Synthorx”) is a biotechnology company developing novel therapeutics by
expanding the genetic alphabet (A-T, G-C, and X-Y) with synthetic biology. The X and Y pair expands the 64 natural codons to 216,
allowing protein synthesis to incorporate non-natural amino acids into new, unique protein therapeutics without re-appropriating cell’s natural codons.
Synthorx’s platform drives site-specific non-natural amino acid incorporation into proteins of any size for at-scale manufacturing. Synthorx has asked Cytovance
Biologics, Inc. (“Cytovance”) to provide a Scope of Work and pricing for process and analytical transfer for [...***...] cGMP Drug Substance and Drug Product manufacturing. This project-specific proposal is provided solely for
Synthorx based on information provided and key assumptions. 
 Issue Date:    Rev 2 – April 12,
2018            Expiration Date:    June 28, 2018 
  

	
	  C. Revision Summary

 Revision 2 

	 	•	 	 Added Payment Table and signature block 

Revision 1 

	 	•	 	 Added clarification that [...***...] 

	 	•	 	 Changed scale to [...***...] 

 

	
	  D. Scope of Work

 1. External Technology Transfer 

To properly execute Synthorx’s Scope of Work, Cytovance may require additional documentation, including, but not limited to:
expression construct and gene information, pertinent development reports, Raw Material Specifications, development batch records, equipment lists, SOPs, [...***...] physicochemical properties, and analytical methods. After Cytovance’s
initial technology transfer package review, any gaps will be discussed with Synthorx. If scope adjustments are required, Cytovance will issue a Change Order and adjusted project timeline for Synthorx approval. 

Objectives 

	 	•	 	 Receive documentation and materials from Synthorx necessary to undertake the Scope of Work 

	 	•	 	 Review information provided 

	 	•	 	 Prepare an updated timeline 

Activities 

	 	•	 	 Documentation - receive the following from Synthorx: 

	 	•	 	 Completed Cytovance cell line questionnaire for the production cell bank and supporting documentation minimally including a
Development/Research Cell Bank (DCB or RCB) with test reports, including sterility, product gene sequence and cell line performance information 

	 	•	 	 Preliminary production process description(s), including raw material source information 

	 	•	 	 Data summary generated during research material production 

	 	•	 	 Transfer analytical method procedure(s), including extinction coefficient 

	 	•	 	 Process and Product Specifications 

	 	•	 	 Preliminary receipt of materials - receive the following from Synthorx: 

	 	•	 	 [...***...] from the cell banks described in the cell line questionnaire 

	 	•	 	 Critical process and analytical reagents 

	 	•	 	 Interim Reference Standard, with documentation and storage and handling conditions 

	 	•	 	 Prepare technology transfer documentation: 

	 	•	 	 Review with Synthorx all documentation and supporting information provided 

	 	•	 	 Clarify outstanding issues via meeting or teleconference to ensure a smooth project transition 

	 	•	 	 Prepare Change Order and updated project timeline, if required 

	 	•	 	 Prepare Cytovance Technology Transfer Checklist to identify and track necessary information exchange 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 3 of 18 

 
  

	 	•	 	 Author Technology Evaluation Report 

Deliverables 

	•	 	 Program timeline 

	•	 	 Technology Evaluation Report 

	•	 	 An approved final Scope of Work (if required) 

2.    Platform Assay Verification/In-House Assay Evaluation 

Objectives 

	•	 	 [...***...] 

Activities 

	•	 	 Review available documentation and discuss any issues with the Synthorx’s technical contact 

	•	 	 Execute assay method verification/evaluation using Synthorx’s comparator reference material 

Deliverables 

	•	 	 Method Verification/Evaluation Report 

3.    Analytical Method Transfer and Qualification 

Objectives 

	•	 	 Transfer and/or qualify product-specific assays from Synthorx per appropriate guidelines: Critical assay execution
factors and parameters have been explored and detailed in a test method procedure. Additional method development work may be required to prepare a Standard Operating Procedure (SOP) for a cGMP environment in the Quality Control Laboratory.

	•	 	 Transfer the following assays and qualify at Cytovance: 

	 	•	 	 [...***...] 

Activities 

	•	 	 Perform method transfer for necessary product-specific assays 

	•	 	 Review received documentation: [...***...] 

	•	 	 Assess technical issues and equipment gaps with Synthorx’s technical contact 

	•	 	 Execute transferred method(s) using Synthorx’s interim Reference Standard and matrix two (2) times

 Note: If a method transfer is unsuccessful, a Change Order may be discussed to initiate development and/or
optimization. Successful method reproduces Synthorx’s results with appropriate analytical parameters based on information provided. 

	•	 	 Prepare Cytovance SOP for each successfully-transferred method or Transfer Report summarizing assay transfer activities
in the event the assay is not transferred 

	•	 	 Prepare Qualification Protocol(s) 

	•	 	 Qualify test methods with respect to applicable parameters: [...***...] 

Note: Not all parameters will be applied to all test methods 

	•	 	 Revise Cytovance SOP(s) as needed and author Qualification Report(s) 

Deliverables 

	•	 	 Cytovance-authored SOP or Transfer Report 

	•	 	 Analytical method Qualification Protocols for each method 

	•	 	 Analytical method Qualification Report for each method 

	•	 	 Approved Cytovance SOP for each method 

4. Upstream Process Transfer and Demonstration 

Note: The Scope of Work assumes a sufficient Process Description is provided during External Technology Transfer defining each unit
operation, stepwise and overall process yield, observed stepwise process volumes, buffer and/or media stability and critical process controls. 

Objectives 

	•	 	 Demonstrate Synthorx’s [...***...] at bench scale 

	•	 	 Assess process manufacturability 

Activities 

	•	 	 Prepare R&D Protocol 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 4 of 18 

 
  

	•	 	 Use the cGMP production cell bank to perform [...***...] 

Note: Includes fermenter preparation, system tests, and control software programming, as necessary 

	•	 	 [...***...] 

	•	 	 [...***...] 

	•	 	 Author Slide Deck Data Summary and R&D Report 

Deliverables 

	•	 	 R&D Protocol 

	•	 	 Slide Deck Data Summary 

	•	 	 Material to support downstream process and analytical development 

	•	 	 R&D Report 

5.    Downstream Process Transfer and Demonstration 

Note: The Scope of Work assumes a sufficient Process Description is provided during External Technology Transfer defining each unit operation, stepwise
and overall process yield, observed stepwise process volumes, buffer stability and critical process controls. 
 Objectives 

	•	 	 Demonstrate the downstream process at Cytovance 

Activities 

	•	 	 Prepare R&D Protocol 

	•	 	 Demonstrate the transferred downstream process using two (2) runs including the following steps:

 1.    [...***...] 

Note: This proposal assumes the refolding step is not dialysis-based, is cGMP-appropriate, and is scalable. 

	•	 	 Author Slide Deck Data Summary and R&D Report 

Deliverables 

	•	 	 R&D Protocol 

	•	 	 Slide Deck Data Summary 

	•	 	 R&D Report 

6. Pilot-Scale Process Demonstration 

Objectives 

	•	 	 Demonstrate the process at bench scale in a continuous run as intended in manufacturing 

	•	 	 Produce Non-cGMP material for tox studies 

Activities 

	•	 	 Prepare two (2) R&D Protocols—one (1) upstream and one (1) downstream 

	•	 	 Prepare batch records, required solutions and chromatography resins 

	•	 	 Use the cGMP production cell bank to perform [...***...] 

	•	 	 Perform [...***...]] ([...***...]) downstream campaigns 

	•	 	 Determine unit operation stepwise and process recovery, and residuals levels for final Drug Substance

	•	 	 Ship bulk Drug Substance to Synthorx 

	•	 	 Author Slide Deck Data Summary and Certificate of Testing 

	•	 	 Author [...***...] ([...***...]) R&D Reports – [...***...] 

Deliverables 

	•	 	 [...***...] ([...***...]) R&D Protocols 

	•	 	 Non-cGMP bulk Drug Substance 

	•	 	 Certificate of Testing 

	•	 	 Slide Deck Data Summary 

	•	 	 [...***...] ([...***...]) R&D Reports 

7. Pre-Production Activities 

7A. Manufacturing Sciences Assessment 

Objectives 

	•	 	 Transfer the intended manufacturing process to the Manufacturing Science and Technology (MS&T) team

	•	 	 Assess and fill equipment gaps 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 5 of 18 

 
  

	•	 	 Order long-lead raw materials 

Activities 

	•	 	 Scale process to intended Cytovance Manufacturing scale 

	•	 	 Complete equipment assessment and gap analysis 

	•	 	 Organize purchase and qualification groups to fill any equipment gaps if any 

	•	 	 Author [...***...] ([...***...]) Internal Technology Transfer Reports – Upstream and Downstream

	•	 	  Order long lead materials 

Deliverables 

	•	 	 Bill of Materials with long-lead items 

	•	 	 [...***...] ([...***...]) Internal Technology Transfer Reports 

7B. Bill of Materials Creation and Component Procurement 

Objectives 

	•	 	 Develop or receive a Bill of Materials (BOM) 

	•	 	 Source required raw materials from qualified vendors 

Activities 

	•	 	 Generate, or receive from Synthorx, and review raw materials specification documents and BOM 

	•	 	 Approve new vendors to provide cGMP material for bulk Drug Substance production 

Note: Vendors previously qualified by Synthorx or Cytovance may not require additional vendor qualification 

	•	 	 Cytovance QA: maintain all vendor and test lab audits 

	•	 	 Prepare and approve Raw Material Specification documents 

	•	 	 Purchase or receive all production components and consumables 

Note: Per 21CFR210.3(b)(3), A component is any ingredient intended for use in the manufacture of a drug product, including those that
may not appear in such drug product. 

	•	 	 Determine required component testing 

Note: Compendial testing for compendial components, manufacturer provided testing/qualified method testing for non-compendial components. 

	•	 	 Execute Component Testing 

	•	 	 Disposition components for manufacturing use 

Note: Some raw material testing may need to be outsourced based on methodologies required. Costs for outsourced testing are not
included in this proposal, and are pending receipt/generation of a Bill of Materials. Cytovance allows conditional release of items for manufacturing use pending acceptable test results. 

Deliverables 

	•	 	 Bill of Materials 

	•	 	 Raw Material Specification documents approved by Cytovance and/or Synthorx 

	•	 	 Vendor and test lab audits 

	•	 	 Components tested and approved for GMP use 

7C. Documentation and Facility Preparation 

Objectives 

	•	 	 Prepare and release process-/product-specific documents necessary for Scope of Work execution; modify as necessary

	•	 	 Prepare facilities and equipment for Non-cGMP and/or cGMP production

 Activities 

	•	 	 Draft necessary documentation to support production and release: batch records, item/material specifications, standard
test methods, Bill of Materials, Product Specifications, and sampling protocols 

	•	 	 Release and maintain all necessary documentation 

	•	 	 Prepare cGMP facility for production: equipment set-up, suite changeover, etc.

 Deliverables 

	•	 	 Released documentation 

	•	 	 Facility release for production 

	•	 	 Release Specifications (Drug Substance/Drug Product) 

	•	 	 Approved batch records 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 6 of 18 

 
  

 8.    Master Cell Bank Preparation 

Objectives 

	•	 	 Use Development Cell Bank to prepare a Master Cell Bank of approximately [...***...] suitable for cGMP production

 Activities 

	•	 	 Prepare Cell Banking Technology Transfer Report and Bill of Materials 

	•	 	 Prepare batch records and accompanying documentation 

	•	 	 Grow sufficient culture for approximately [...***...] 

	•	 	 [...***...] 

	•	 	 [...***...] 

	•	 	 [...***...] 

	 	•	 	 [...***...] 

	 	•	 	 [...***...] 

	•	 	 Manage testing of Master Cell Bank in accordance with ICH guidelines at third party subcontractor 

	•	 	 Provide on-site storage of Cell Banks 

Note: To minimize risk, Cytovance recommends additional off-site storage of portions of Master
Cell Banks at an approved bio-repository.Price to be determined later with third party vendor. 

	•	 	 Ship cell bank as directed by Synthorx in a qualified [...***...] with data logger 

Deliverables 

	•	 	 Cell Banking Technology Transfer Report 

	•	 	 Bill of Materials 

	•	 	 Approximately [...***...] 

	•	 	 Certificate of Analysis 

	•	 	 Appropriate documentation regarding genotype, phenotype, and culture testing 

	•	 	 Final Bank Disposition 

9. Non-cGMP Production 

Objectives 

	•	 	 Perform [...***...] 

	•	 	 Use the run to finalize manufacturing documentation 

	•	 	 Test the product to allow final cGMP Product Specification to be agreed upon 

	•	 	 Demonstrate the scalability of the production and purification process 

	•	 	 Produce Non-cGMP material 

Activities 

	•	 	 Perform [...***...], draft batch records, and released raw materials 

	•	 	 Address potential problems caused by scale up and track specific contaminants [...***...]] across the process

	•	 	 Analyze process performance and product characteristics and compare with process demonstration results

	•	 	 Cytovance in-process testing to include as appropriate: 

	 	•	 	 [...***...] 

Note: If in-process testing exceeds above per batch, a change order will be issued for
additional tests. 

	•	 	 Aseptically fill bulk Drug Substance into sterile bulk containers 

	•	 	 Test product against pre-determined specifications. Tests to be performed may
include the following: 

	 	•	 	 [...***...] 

	•	 	 Author testing reports and Engineering Run Report 

Deliverables 

	•	 	 Executed batch records 

	•	 	 Cytovance testing reports 

	•	 	 Bulk filled Drug Substance suitable for use in non-clinical studies and
stability studies 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 7 of 18 

 
  

	•	 	 Engineering Run Report 

10. Reference Standard Preparation 
 Objectives 

	•	 	 Prepare analytical reference sample for support of further development, stability studies and release testing

 Activities 

	•	 	 Fill into final container 

Note: Cytovance is currently able to fill a maximum of [...***...] 

	•	 	  Store vials of Reference Standard at an agreed upon temperature 

	•	 	 Manage additional outsourced testing for characterization 

Deliverables 

	•	 	 Vialed Reference Standard 

	•	 	 Vendor-supplied Reference Standard report 

11. Non-cGMP Drug Product Fill/Finish 

Objectives 

	•	 	 Perform Non-cGMP fill of Engineering material 

Activities 

	•	 	 Agree upon the concentration, vial configuration, and fill volume with Synthorx prior to fill 

	•	 	 Perform Non-cGMP fill of Drug Substance. The manufacturing process may include:

	 	•	 	 [...***...] 

	•	 	 Drug Product Testing may include: 

	 	•	 	 [...***...] 

	•	 	 Provide testing results 

Deliverables 

	•	 	 Non-cGMP filled Drug Substance 

	•	 	 Executed batch records 

	•	 	 Analytical Test Results 

12. cGMP Productions 
 Note: Cytovance
recommends completion of a Non-cGMP Engineering Run prior to cGMP production. Should Synthorx chose not to complete an Engineering run, they will be responsible for the cGMP run in its entirety. If the cGMP
run fails for any reason, the run will be terminated, and Synthorx will be responsible for all associated costs for this run and any repeat runs. 

Objectives 

	•	 	 Perform [...***...] 

	•	 	 Manufacture at the same scale as the engineering batch to minimize the risk of issues arising during cGMP processing

 Activities 

	•	 	 Manufacture [...***...] under cGMP conditions 

	•	 	 Cytovance in-process testing to include as appropriate: 

	 	•	 	 [...***...] 

Note: If in-process testing exceeds above per batch, a change order will be issued for
additional tests. 

	•	 	 Aseptically fill bulk Drug Substance into sterile bulk containers 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 8 of 18 

 
  

	•	 	 Test product against pre-determined specifications. Tests to be performed may
include the following: 

	 	•	 	 [...***...] 

	•	 	 Prepare disposition documentation 

Deliverables 

	•	 	 Bulk-filled Drug Substance 

	•	 	 Certificate of Analysis 

	•	 	 Certificate of Conformance or disposition document 

	•	 	 Lot file assembly 

13. cGMP Drug Product Fill/Finish 

Objectives 

	•	 	 Perform cGMP Drug Product Fill 

Activities 

	•	 	 Perform [...***...]. The manufacturing process may include: 

	 	•	 	 [...***...] 

	•	 	 Drug Product Testing may include: 

	 	•	 	 [...***...] 

	•	 	 Prepare Certificate of Analysis, Certificate of Conformance, and Lot File Assembly 

Deliverables 

	•	 	 Released cGMP Drug Product 

	•	 	 Executed batch records 

	•	 	 Certificate of Analysis 

	•	 	 Certificate of Conformance or disposition document 

	•	 	 Lot File Assembly sufficient to support [...***...] 

14. Stability Testing Program 

Objectives 

	•	 	 Perform stability studies on Drug Substance, Reference Standard, and Drug Product made at Cytovance

 Activities 

	•	 	 Define storage container/closure, storage temperatures, time points, test article total mass and concentration, and test
methods in a Study Protocol prior to execution 

	•	 	 Test Drug Substance (DS), Reference Standard (RS), and Drug Product (DP) stability. A preliminary protocol is below:

 Preliminary Stability Protocol 

[...***...] 
  

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 9 of 18 

 
  

 [...***...] 

Deliverables 

	•	 	 Stability Study Protocol 

	•	 	 Stability Report at each time point 

15. Column Cycling in Non-cGMP and cGMP Production 

Objectives 

	•	 	 Provide the option to cycle columns during Non-cGMP and cGMP manufacturing

 Note: Cytovance will include [...***...]. 

16. Individual Vial Labeling and/or Inspection 
 Objectives 

	•	 	 Perform custom labeling and inspection of all Synthorx’s Drug Product vials —
Non-cGMP and cGMP 

 Activities 

	•	 	 Agree with Synthorx on label copy 

	•	 	 Send label copy to Synthorx for review and approval 

	•	 	 Apply customer vial label to Drug Product vials 

	•	 	 Perform vial inspection 

Deliverables 

	•	 	 Labeled and/or inspected Drug Product 

17. Program Management 
 Objectives 

	•	 	 Provide overall management of the program per the agreed scope and terms of the contract 

	•	 	 Ensure project team alignment about contract milestones and deliverables 

	•	 	 Ensure customer satisfaction with all aspects of the program through effective and timely communication

 Activities 

	•	 	 Serve as primary contact for Synthorx 

	•	 	 Manage and coordinate communications between the companies and program team members 

	•	 	 Host program team meetings biweekly or as required (via teleconference or at Cytovance facilities) 

	•	 	 Anticipate and report deviations from program scope and timeline 

	•	 	 Manage activities, timelines and milestone deliverables 

	•	 	 Plan and manage appropriate resource availability 

	•	 	 Provide technical summaries and updates 

	•	 	 Align program team 

Deliverables 

	•	 	 Timely communication on project progress and events 

	•	 	 Program updates 

	•	 	 Gantt chart and/or document tracking tool, as appropriate 

 

	
	  
   E. Price Matrix

 

 The price estimate below is based on client information and current assumptions. Pricing may be modified after detailed
technical review, receipt of additional information, and mutual development and agreement of a detailed Scope of Work. 
 [...***...] 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 10 of 18 

 
  

 [...***...] 
  

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 11 of 18 

 
  

 [...***...] 
  

	
	  
   F. Storage and Shipping
Assumptions
  

 Storage Assumptions and Matrix 

	•	 	 Cytovance will store Process Development or in-process samples for
[...***...] following Drug Substance lot disposition. After [...***...], Synthorx will be notified that samples will disposed of if shipping arrangements are not coordinated within [...***...]. 

	•	 	 Cytovance will store Master and/or Working Cell Banks for [...***...] after bulk Drug Substance lot disposition
at [...***...]. Extended storage [...***...]. 

 Note: Cytovance requires that at least
[...***...]% of each Cell Bank vial count be stored at an offsite cell bank storage facility 

	•	 	 Cytovance will store filled Drug Substance and/or Drug Product for [...***...]. Extended storage
[...***...]. 

	•	 	 Stability sample storage will be billed monthly per the matrix below based on number of vials stored at each
temperature 

	•	 	 Vials larger than [...***...] size will have additional charges applied on top of the charges listed in the
matrix. All storage charges will be confirmed with Synthorx prior to billing. 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 12 of 18 

 
  

 [...***...] 

Bulk Storage Assumptions and Matrix 

	•	 	 Cytovance will store bulk in-process materials (i.e. held harvest material,
column eluates, etc.) and/or Drug Substance for [...***...]. Extended storage [...***...]. All storage charges will be confirmed with Synthorx prior to billing. 

[...***...] 
 Sample Shipping
Assumptions and Matrix 
 Due to the complexity of each client’s shipping configuration an estimate is provided in the table below that
outlines the shipping cost based on Cytovance’s standard packout configuration and a [...***...] vial. Synthorx will be billed for all Process Development or QC shipments per the following table (by sample shipment or shipments containing
up to [...***...]). 
 [...***...] 
  

	•	 	 Shipment of in-process testing samples retains, and bulk Drug Substance and/or
filled Drug Product will be invoiced separately 

	•	 	 Boxes over 75 pounds will incur a heavy box surcharge of $[...***...] per box 

	•	 	 [...***...] 

Cell Bank and Bulk Drug Substance and/or Filled Drug Product Shipping Assumptions and Matrix 

Cytovance has relationships with major shipping companies such as FedEx, World Courier and UPS, and works with each client on unique shipping
configurations. If necessary, Cytovance will also make recommendations based on our experience to ensure products reach their destination safely. Shipping Includes: 

	•	 	 Shipping management and preparation 

	•	 	 Product shipment verification: Cytovance to Synthorx-specified United States destination 

	•	 	 Domestic shipping documentation preparation 

Note: Does not include freight charges, which will be billed as a pass through 

									
	Packaging and Shipment	  	Unit    	  	 	Unit Price      	 	  	Total Price  
	Cell Bank Includes shipment in Dewar with shiplog and return of Dewar to Cytovance	  	TBD    	  	 	$[...***...]    	 	  	TBD
	Bulk Drug Substance and/or Filled Drug Product Includes Temp-tale	  	TBD    	  	 	$[...***...]    	 	  	TBD

  

	
	  
   G. Payment Terms and
Program Assumptions
  
  

 Payment Terms 

	•	 	 Pricing-information for the-provided Scope of Work will be valid until the
expiration date. If the proposal is not signed by the expiration date, Cytovance reserves the right to adjust pricing per current policies. 

	•	 	 Invoicing milestones are in the Payment Table 

	 	•	 	 Prepayment, identified in the Payment Table, is non-refundable

	 	•	 	 All Cytovance milestone invoices and pass through material reconciliations will be
e-mailed to Synthorx Accounts Payable 

	 	•	 	 Scope of Work milestones will be invoiced as defined in the Payment Table and payment is due net [...***...] from
Cytovance invoice 

	 	•	 	 Program Management fees will be charged for each month between contract signature and PD material shipment or cGMP lot
disposition 

	 	•	 	 Additional services will be charged at a labor rate of $[...***...]/hr for standard services and
$[...***...]/hr for director-level services and above, plus reasonable travel expenses if required 

	 	•	 	 A [...***...]% administrative fee will be applied to outsourced testing fees for Cytovance management and
coordination 

	 	•	 	 A [...***...]% administrative fee will be applied to outsourced material and/or waste disposal fees for Cytovance
management and coordination 

	•	 	 Project-specific materials costs, excluding general-use items, will be passed
to or purchased by Synthorx 

	 	•	 	 Chromatography resin/columns for use in manufacturing will be purchased by Synthorx and drop-shipped to Cytovance

	 	•	 	 Raw materials/components and outsourced services will be invoiced as purchase orders are placed with suppliers; payment
is due upon receipt of Cytovance invoice. If costs exceed projections, Cytovance will obtain Synthorx’s written approval for additional costs. 

	 	•	 	 Any additional capital requirements and associated equipment qualification will be purchased by Synthorx, unless
arranged as a pass-through cost with Cytovance in a Change Order. 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 13 of 18 

 
  

	 	•	 	 If Cytovance purchases equipment or materials, and passes the costs to Synthorx, a [...***...]% administrative fee
will apply to cover acquisition, inventory, quarantine, release testing, storage, dispensing, staging and cGMP documentation 

	 	•	 	  Cytovance will create [...***...]; additional new specifications [...***...] 

	 	•	 	 If components or excipients must be sourced by a vendor not qualified by Cytovance, a fee of $[...***...] per paper
audit and/or $[...***...] per on-site vendor audit will apply, not including client-approved, product-specific vendor audit costs, which will be Synthorx’s responsibility. 

	•	 	 Cytovance is not a long-term storage facility 

	 	•	 	 Cytovance will store the samples, and/or Drug Substance, and/or Drug Product for [...***...] after fill at
[...***...]. Extended storage [...***...] as identified in the shipping and storage section of this proposal. 

	 	•	 	 Cytovance will store raw materials for a period of [...***...] after release at [...***...]. Extended storage
[...***...]. If raw materials expire, disposal costs will be billed as a pass-through with a [...***...]% administration fee, or Synthorx will be responsible for any shipping and handling costs incurred for shipment to a client-specified
destination. 

	 	•	 	 Cytovance will store used client-supplied resins and/or columns for [...***...] after production completion at no
additional charge. Extended storage [...***...], inclusive of all columns and/or resins. 

 Program Assumptions 

	•	 	 This proposal is based on Cytovance’s understanding of Synthorx’s requirements. Additional information obtained
during work, because of work performed, or changes to the project assumptions, may impact the Scope of Work and project costs; changes will be agreed upon by Synthorx and Cytovance in writing, typically a Change Order, before performance.

	•	 	 Product-specific assays are defined for this proposal as those assays requiring procedures or reagents specific for
Synthorx’s program, including, but not limited to, [...***...] 

	•	 	 Cytovance guarantees compliance with appropriate cGMP standards, but does not guarantee meeting draft specifications or
target batch quantities. Cytovance staff will follow all batch instructions. 

	•	 	 Assays not performed by Cytovance will not appear on the specification sheet unless a Cytovance QA representative has
audited the testing laboratory. Such audits will be performed at Synthorx’s request and cost. 

	•	 	 Stability testing costs are indicated per condition, inclusive of pull date, temperature, and storage according to the
preliminary protocol presented in the Scope of Work. If testing or condition adjustments upon final Stability Protocol development, a Change Order may be issued. 

	•	 	 If full qualification for Synthorx-specific excipients/components is needed, beyond the above Scope of Work, additional
charges will apply 

	•	 	 Synthorx is responsible for [...***...] and Cytovance will use Synthorx’s designated shipper &
account number. Title transfer of any material shipped from Cytovance will take place at FOB shipping point. 

	•	 	 Synthorx is responsible for [...***...] for Cytovance staff attending meetings requested by Synthorx not at
Cytovance 

	•	 	 If QP release is required for any deliverables, [...***...] will be incurred by Synthorx 

	•	 	 Cytovance and/or Synthorx may wish to issue a press release relating to this contract; written approval must be obtained
from the other party prior information disclosure 

  

	
	  H. Business Philosophy

 Cytovance focuses on a strong client experience and was founded on the premise that an understanding of our
customers’ technical and business needs is required to efficiently serve the market. We offer a comprehensive commercial-quality manufacturing service portfolio under reasonable terms and can provide continuity for the project duration. We
believe technical excellence and appropriate compliance delivery is a given, and that we must differentiate ourselves and add significant value to our customers. Our business model allows us to meet customer needs by providing the following: 

 

	•	 	 Multi-product cGMP manufacturing facility not retro-fitted space or converted from single/limited product use

	•	 	 Opportunity to grow: Facility design includes expansion space for larger scale production on a multi-product or
client-specific basis 

	•	 	 Comprehensive service offering that can provide a turnkey solution, but which allows clients maximum flexibility to take
only the services they require. We are happy to undertake smaller stand-alone projects, and strive to allow our clients to focus time and resources on their core competencies. 

	•	 	 Professional team with significant client-side experience supplemented by sound biopharmaceutical services market
knowledge. We have a great appreciation for the larger drug development process picture, and use these experiences to build strong collaborative relationships and to ensure that we are meeting customer needs. 

	•	 	 Maximum strategic flexibility: We avoid use of royalty-bearing intellectual property unless specifically requested, and
ensure that all methods, processes and systems are transferable. We hope to develop long-term relationships but will provide our full support if it becomes necessary to transfer a process to an alternative manufacturing site. 

	•	 	 Understanding products we deliver are more than therapeutic proteins and associated documentation; processes we develop
belong to our customers and must be economically viable, robust, compliant, scalable and transferable. 

	•	 	 Know-how allowing customers to fully support their process throughout its
lifecycle 

	•	 	 Range of strategic collaborators providing “seamless” access to necessary services not offered by Cytovance

	•	 	 Executive-level oversight of every customer relationship 

 

	
	  I. Production Facility

 Cytovance is a full-service Contract Development and Manufacturing organization (CDMO) in Oklahoma City, OK employing 220
people. Microbial host services include strain development and process development for cGMP production at the 10 L, 200 L, and 1,000 L scales, with 300 L SUF technology being added in 2018. Mammalian services include cell line development and
process development for cGMP production at the 100 L, 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 14 of 18 

 
  

 250 L, 500 L, and 1,000 L scales with a planned expansion into 2,000 L production for early 2019. With
full Analytical Development and Quality Control testing groups, Cytovance provides method transfer, development, qualification, and validation, and in-process, release, and stability testing. Cytovance also
has clinical-grade, liquid vial fill/finish capabilities, Master, Working, and End-of-Production cell banking, viral validation, and Process Characterization and
Validation services. Cytovance operates out of four (4) facilities - three (3) located within the Oklahoma University Research Park, close to the city’s central business district encompassing over 100,000 square feet of laboratories,
cGMP Drug Product and mammalian manufacturing, and administration space. Just north of the main campus is a 30,000 ft2 microbial cGMP manufacturing building, and a 100,000 ft2 cGMP warehouse. Cytovance welcomes appropriate Synthorx representatives to tour the facilities and perform a detailed review of Cytovance’s facility design, equipment, validation, process flow,
and quality systems. 
 Analytical Test Equipment 
  

					
	Test	  	Quality Control Equipment	  	Analytical Development Equipment
	pH	  	Beckman 350 pH meter	  	Mettler Toledo
	Conductivity	  	Mettler	  	Mettler
	Osmolality	  	Advanced Instruments Micro-Osmometer 3300	  	N/A
	% Purity/Aggregates	  	Waters 2695 HPLC	  	Agilent 1100/1200 HPLC/Waters 2695 HPLC/Acquity H-Class Bio
UPLC
	Bioburden	  	 Millipore Milliflex single head pump system

Certified biological safety cabinet
 Precision Incubator
	  	N/A
	Endotoxin	  	Molecular Devices Spectra Max 384 plus UV/Vis plate reader/ Endosafe PTS	  	Molecular Devices Spectra Max M2e/ Endosafe PTS
	Protein content	  	 Beckman Coulter DU 730 spectrophotometer

Molecular Devices Spectra Max 384 Plus
 Molecular Devices Spectra Max M2e
	  	 Beckman Coulter DU 730
spectrophotometer
 Eppendorf Biophotometer
 Molecular Devices Spectra Max
M2e

	ELISA	  	 Lab Line Instruments Titer Plate Shaker

Beckman Coulter MW96/384 plate washer
 Molecular Devices Spectra Max 384 plus

Molecular Devices Spectra Max M2e
 BioTek Synergy / neo2 Multimode Reader
	  	 Lab Line Instruments and VWR
Titer Plate Shakers
 Beckman Coulter MW96/384 plate washer
 Molecular Devices
Spectra Max M2e
  
 Forte Bio Octet Red BLI

	SDS-PAGE	  	 Bio Rad Power Pac

Bio Rad & Invitrogen electrophoresis cells
 SYNGENE G:BOX F3 Gel
Documentation System
 Un-Scan-It Gel Analysis Software
	  	 Bio Rad Power Pacs

Bio Rad & Invitrogen Electrophoresis cells

Un-Scan-It Gel Analysis Software

	CGE or CE-SDS	  	Beckman Coulter ProteomeLab PA 800/PA 800plus	  	Beckman Coulter ProteomeLab PA 800plus
	IEF/cIEF/icIEF	  	 Bio Rad Power Pac

GE Amersham Biosciences multiphor II
 VWR Model 1160S Chiller

SYNGENE G:BOX F3 Gel Documentation System/ Un-Scan-It Gel Analysis Software

Beckman Coulter ProteomeLab PA 800/PA 800plus
 Protein Simple iCE280 System
	  	 Bio Rad Power Pac

GE Amersham Biosciences multiphor II
 VWR Model 1160S Chiller

Protein Simple iCE280 System
 Beckman Coulter ProteomeLab PA 800 Plus

	Immunoblotting	  	 Bio Rad Power Pac

Bio Rad & Invitrogen electrophoresis cells
 Bio Rad Trans Blot Semi-dry Transfer Cell
 SYNGENE G:BOX F3 Gel Documentation System
	  	 Bio Rad Power Pac

Bio Rad & Invitrogen Electrophoresis/Transfer cells
 Bio Rad Trans Blot Semi-dry Transfer Cell

	Residual DNA	  	 Applied Biosystems Quant Studio 6 RT PCR
System
 Applied Biosystems Step One RT PCR System
	  	 
	Sialic Acids/ Glycoprofile	  	 	  	 Dionex BioLC System –
HPAED
 Acquity H-Class Bio UPLC- FLD Detector

 Upstream and Downstream Equipment 

					
	Function	  	cGMP Manufacturing-Equipment-	  	Process-Development Equipment
	Fermenter Systems	  	
•  10 L Bio-Flo 320

•  200 L Biostat D200 Sartorius Fermenter

•  300 L ThermoFisher HyPerforma SUF

•  1,000 L Biostat D1000 Sartorius Fermenter
	  	
•  5 L Sartorius Biostat Aplus (8)

•  14 L New Brunswick BioFlo 310 (1) and 320 (1)

  
 CONFIDENTIAL 

 P a g e | 15 of 18 
  

					
	Function	 	cGMP Manufacturing-Equipment-	 	Process-Development Equipment
	Cell Processing	 	
•  Alfa Laval LAPX 404 Disk Stack Centrifuge

•  Alfa Laval High MBPX 810 Disk Stack Centrifuge

•  Pneumatic Scale Angelus P12 Centrifuge

•  GEA Homogenizer GEA Niro Soavi Ariete NS3015H

•  GEA Homogenizer Niro Soavi Panther NS3006L

•  GEA homogenizer Niro Soavi Panda 2000
	 	
•  Beckman Coulter J-26XP

•  Beckman Coulter 367160

•  GEA Homogenizer Niro Soavi Panda 1000+

•  Beckman Coulter J-25

•  VWR Clinical 200

•  Angelus Powerfuge Pilot Continuous Centrifuge

	Purification Systems	 	
•  Mixing and depth filtration capabilities up to 1,000 L

•  Refolding and PEGylation capabilities up to 1,000 L

•  ASI Impulse Single Use Mixer (two (2) x 5,000 L)

•  1 in AKTA Process (up to 2000 LPH, gradient capability)

•  10 mm AKTA Process (27 to 400 LPH, gradient capability)

•  AKTA Ready, single-use (3 to 510 LPH, gradient
capability)
 •  Large inventory of columns up to 80 cm

•  Millipore membrane holder (0.1 to 5.0 m2 capacity)

•  TangenX membrane holder (1.0 to 30.0 m2 capacity)
	 	
•  Refolding with imPULSE 30L SUM

•  Mixing and Depth filtration capabilities up to 30L

•  AKTA Pure (2), AKTA Explorer (2)

•  AKTA Avant (2), AKTA Pilot

•  GE 10 mm Bioprocess Skid

•  Chromatography columns 0.6 to 30.0 cm

•  Scilog TFF systems with holders to 0.5 m2 (5)

  

	
	  
   J.
Personnel
  

 Jesse McCool, Ph.D., Senior Vice President of R&D Services 

Dr. Jesse McCool has over 10 years’ experience in microbial process development, characterization and technology transfer. Prior to Cytovance,
Jesse was the Director of Process Development at Lonza Biologics; while there, he expanded offerings in Microbial R&D Services and improved market presence through driving new technologies development, particularly in the areas of strain
development, Design of Experiments (DoE), and late-stage program support. He helped to adopt a QbD framework for supporting pre-validation activities, supported numerous cGMP campaigns as a subject matter
expert, and has significant experience in six-sigma and Operational Excellence. As an established speaker, he has chaired and presented at various industry conferences. He has written and contributed to
numerous published papers on topics including fermentation process design and microbial expression technologies. Prior to Lonza, Jesse was a Scientist at Mascoma Corporation and Postdoctoral Research Associate at the Thayer School of Engineering at
Dartmouth College. He holds a B.S. in Environmental Sciences and a Ph.D. in Microbiology, both from the University of Massachusetts Amherst, and recently completed advanced coursework in Microbial Physiology and Fermentation Technology at Technische
Universiteit Delft in The Netherlands. 
 Mike O’Mara, Senior Vice President of Manufacturing Operations 

Mike O’Mara has more than 23 years’ experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell therapy
manufacturing processes ranging from Preclinical/Phase I through Commercial. Prior to Cytovance, Mike worked at DynPort Vaccine Corporation as Senior Director of Manufacturing, and was TissueGene’s Vice President of Manufacturing, and worked
for Lonza Biologics for 18 years in several operations and manufacturing positions. Mike has been part of numerous technology transfers, operational excellence initiatives, FDA and Regulatory agency audits, growing organizations, and manufacturing
expansions/build-outs. Mike holds a B.S in Microbiology from The University of Maryland. 
 Edwin Miranda, Vice President of Quality 

Mr. Miranda has over 33 years’ experience in biologics, medical device, and pharmaceutical manufacturing quality management. Prior to Cytovance,
Edwin oversaw the UCB Pharma Quality Assurance team in a successful Keppra® FDA approval and New Drug Application (NDA)launch. He was Vice President of Quality Assurance URL Mutual
Pharmaceuticals, Inc., and Director of Quality at both Legacy Pharmaceutical Packaging and Piramal Critical Care, Inc., where he managed quality systems, oversaw regulatory compliance functions, and developed successful remediation plans for 483
observations. Edwin has experience applying process improvement approaches for quality systems, including time and cost reductions for Quality Control laboratories and Quality Assurance teams. He holds a B.S. in Biology & Chemistry from
Angelo State University in San Angelo, TX. 
 Naomi Seresinhe, M.B.A., Vice President of Program Management 

Naomi Seresinhe has over 15 years’ experience in program management — including four years at Cytovance, and four years’ experience in
upstream Research and Development. She has experience in process improvement, as well as financial analysis for financial and manufacturing industries. Naomi currently oversees the Program Management Team at Cytovance, and holds a B.Sc. in
Microbiology from University of Saskatchewan and an M.B.A. from City University in Washington State. 
 Stephanie Wickham, Ph.D., Director of Manufacturing
Sciences 
 Dr. Stephanie Wickham has over 12 years’ experience in research and industry cell culture and protein purification.
Following graduate work with transfection, fermentation, and purification of proteins from mammalian and microbial hosts, she performed a post-doctoral fellowship in at the University of Oklahoma Health Sciences Center’s Cell Biology department
developing small molecule enzyme inhibitors for an enzyme transformed into yeast and purified. Her focus at Cytovance has been process transfer into manufacturing, designing process scale-up processes and
documentation, and leading the MST team as they help every client transition from bench- to full-scale clinical supply batches. Stephanie received a B.S. in Chemistry and Mathematics from Southwestern Oklahoma State University, and a Ph.D. in
Microbiology and Immunology from University of Oklahoma Health Sciences Center, and completed a professional education program in fermentation at Massachusetts Institute of Technology. 

  
 CONFIDENTIAL 

 P a g e | 16 of 18 

 
  

 Frank Agbogbo, Ph.D., Director of Fermentation 

Dr. Frank Agbogbo has over 13 years’ experience in academia and industry. Prior to Cytovance, Frank was a scientist at Novozymes, ICM, Inc., and
Mascoma Corporation; he also served as Application Technology Manager at Mascoma. His background includes fermentation development, optimization, and scale-up, and enzymatic hydrolysis. Frank provided
technical oversight responsibilities on piloting and commercial use of MGT products, and has authored several related publications. He has expertise with multiple microbial host strains including P. Stipitis, C. thermocellum, S.
cerevisiae, and E. coli. Frank holds a B.S. in Chemical Engineering from Kwame Nkrumah’ University of Science and Technology, and a Chemical Engineering Ph.D. from Texas A&M University. 

Seth Fisher, Director of Purification Development 

Mr. Fisher, a Boston University Trustee Scholar, has over 20 years’ experience in research, process development
scale-up and manufacture of complex biologics for both biopharmas and CMOs using mammalian and microbial expression platforms. As a trained protein biochemist, Seth has focused his career on the design and scale-up of purification methodologies for complex proteins, enzymes and vaccine products for a wide range of clinical areas. His industry experience includes positions at Amgen, GSK, Avid Bioservices, and Stamford
BioProcess Technologies. His 10+ years at Amgen offered him broad purification experiences for monoclonal antibodies, peptides and Fc-peptide fusions, enzymes, cytokines, kinases, antiangiogenic factors and
vaccine proteins; his work at Amgen included extensive refolding process development of E. coli-derived inclusion bodies and subsequent downstream processes development. While at GSK he was involved in discovery of a novel kinase p38 and a
HIV protease as well as purification scale-up and production. 
 David Schmidt, Director of Analytical Development

 David Schmidt has over 5 years’ experience in industry at Cytovance Biologics and over 6 years’ experience working in clinical
laboratories at Integris Medical Center and Excalibur Pathology Labs. He has hands-on experience with analytical method development, optimization, and qualification. David currently oversees the Analytical
Development lab at Cytovance, which involves transferring client analytical methods, verification and evaluation of in-house platform assays, new method development, drafting SOPs, and transferring methods to
Quality Control. David has a B.S. in Microbiology and Chemistry from the University of Science and Arts of Oklahoma, and a B.S. in Microbiology from the University of Oklahoma. 

Rabi Prusti, Ph.D., Executive Director of Quality Control 

Dr. Rabi Prusti has 5 years’ academic and 25 years’ Biotech and Biopharmaceutical Industry experience in Research and Development, Quality
Systems, Quality Control, Compliance, Analytical Method Development and Validation, CMC Documentation, Project Management, cGMP/GLP/FDA/USP/ICH compliance. Prior to Cytovance, he held positions at CancerVax, Protein Helix, BioSpecifics Technologies,
VI Technologies, and Curative Technologies. Rabi has a strong background in Protein Biochemistry, Signal Transduction and Photobiology, 36 published research articles and has presented 56 abstracts. He has product development experience under both
new product and commercial platforms with human growth factors, virus free plasma proteins, bacterial proteins, cell-based immunotherapy products, and monoclonal antibodies. Rabi has a B.S. and M.S. in the Life Sciences, M.Phil. in Developmental
Biology and Bioenergetics from Jawaharlal Nehru University, New Delhi. He holds a Ph.D. in Biochemistry from Texas Tech University and completed his post-doctoral research at the University of Washington, School of Medicine in Seattle. 

 

	
	  K. Payment Table

 [...***...] 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 17 of 18 

 
  

 [...***...] 

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL 

 P a g e | 18 of 18 

 
  

 [...***...] 

AUTHORIZATION 
  

									
	 Cytovance Biologics, Inc.
	  		  	 Synthorx, Inc.

					
	 By:
	  	 /s/ Jesse McCool
	  		  	 By:
	  	 /s/ Laura Shawver

					
	 Name:
	  	 Jesse McCool
	  		  	 Name:
	  	 Laura Shawver

					
	 Title:
	  	 Sr. VP R&D Services
	  		  	 Title:
	  	 President and CEO

					
	 Date:
	  	 17 Apr 18
	  		  	 Date:
	  	 4/16/2018

  
 ***Confidential Treatment
Requested 
 CONFIDENTIAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]